

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 6 : C07C 43/23, 69/017, 49/517, 205/45, 205/06, 205/18, 39/23, A61K 31/085, 31/22, 31/12, 31/04, 31/05</p>	A1	<p>(11) International Publication Number: WO 95/11215</p> <p>(43) International Publication Date: 27 April 1995 (27.04.95)</p>
<p>(21) International Application Number: PCT/US94/11852</p> <p>(22) International Filing Date: 17 October 1994 (17.10.94)</p> <p>(30) Priority Data: 08/141,492 21 October 1993 (21.10.93) US</p> <p>(71) Applicant: LIGAND PHARMACEUTICALS INCORPORATED [US/US]; 9393 Towne Centre Drive, San Diego, CA 92121 (US).</p> <p>(72) Inventors: JONES, Todd, K.; 805 Highland Drive, Solana Beach, CA 92075 (US). HAMANN, Lawrence, G.; Apartment 38, 7085 Charmant, San Diego, CA 92122 (US). FARMER, Luc; 3245 Caminito East Bluff, La Jolla, CA 92037 (US). JOHNSON, Michael, G.; 1630 Reed Avenue, San Diego, CA 92109 (US). GOLDMAN, Mark, E.; 4372 Corte de la Fonda, San Diego, CA 92130 (US).</p> <p>(74) Agent: MELVILLE, Hope, E.; Lyon & Lyon, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CL, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>


(54) Title: NON-STEROID ANDROGEN RECEPTOR ANTAGONISTS

(57) Abstract

Non-steroidal compounds of formulae (I) or (II), wherein the variables are as defined in the description, which are high affinity, high specificity ligand antagonists for the androgen receptor are disclosed. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by the androgen receptor and for treating patients requiring androgen receptor antagonist therapy.



(I)



(II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo			SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

DESCRIPTION

NON-STEROID ANDROGEN RECEPTOR ANTAGONISTS

Field of the Invention

This invention relates to intracellular receptors and ligands therefor. More specifically, this invention relates to compounds which are non-steroidal androgen receptor antagonists, and methods for use of such compounds or ligands.

Background of the Invention

A central problem in eukaryotic molecular biology continues to be the elucidation of molecules and mechanisms that mediate specific gene regulation in response to molecular inducers such as hormones. As part of the scientific attack on this problem, a great deal of work has been done in efforts to identify molecular inducers which are capable of mediating specific gene regulation.

Although much remains to be learned about the specifics of gene regulation, it is known that certain small molecule, non-peptide hormones and similarly acting vitamins and vitamin metabolites (collectively hereinafter called "hormones") modulate gene transcription by acting in concert with intracellular components, including intracellular receptors and discrete DNA promoter enhancer sequences known as hormone response elements (HREs).

These hormones, acting through, and as "ligands" for, their intracellular receptors, directly regulate hormone-responsive genes (and perhaps other important genes which are not directly hormone-responsive). Natural ligands for intracellular receptors are synthesized in the body or may be taken in as a component of food. It has also been shown that compounds other than the natural ligands can act upon intracellular receptors to regulate hormone-responsive genes. For example, some natural product

derivatives and synthetic compounds also function as ligands for these receptors.

Intracellular receptors form a class of structurally-related genetic regulators scientists have named "ligand dependent transcription factors." Regulation of a gene by
5 such factors requires both the intracellular receptor itself and a corresponding ligand which has the ability to selectively bind to the intracellular receptor in a way that affects gene activity. Until bound by a ligand, the
10 intracellular receptor is unable to exert an effect on the gene. Hormone or other ligand molecules in the fluid surrounding a cell pass through the outer cell membrane by passive diffusion. Once inside the cell, the ligand binds to specific intracellular receptor proteins, creating a
15 ligand/receptor complex. The binding of the ligand to its receptor induces a change in the shape of the intracellular receptor. This conformational change is believed to expose regions of the intracellular receptor that permit the intracellular receptor/ligand complex to bind
20 to a specific subset of genes present in the cell's DNA in the cell nucleus.

The blueprint to build specific proteins is encoded in the DNA sequence of each gene. This blueprint is copied in a process referred to as "transcription," to give rise
25 to the actual template for the production of specific proteins, messenger RNA or "mRNA". The MRNA then moves from the cell's nucleus into the cytoplasm and is translated, which results in the production of proteins encoded in the MRNA. Accordingly, a reduction in the transcrip-
30 tion of MRNA reduces the production of the specific proteins.

Once the intracellular receptor/ligand complex binds to the specific site on the DNA, it alters the amount of the protein encoded by the gene that the cell is directed
35 to produce, by altering the amount of MRNA transcribed by that gene. A ligand which binds an intracellular receptor and mimics the effect of the natural ligand is referred to

as an "agonist" ligand. A ligand that inhibits the effect of the hormone is called an "antagonist." Intracellular receptors are referred to as "ligand-dependent transcription factors" because their activity is dependent upon the binding of their hormones or other ligands, which are necessary to drive the intracellular receptor into its active conformation.


The intracellular receptors form a large family of proteins that are closely related in structure. They are important drug targets, and many drugs currently on the market are ligands for these intracellular receptors. Not surprisingly, the structural similarity of the intracellular receptors often results in cross-reactivity between a drug and one or more intracellular receptors other than the desired target intracellular receptor. It is apparent, therefore, that there is a need to find alternative ligands (agonists and/or antagonists) which are readily available for therapeutic administration, have added specificity for particular intracellular receptors, and have increased activity.

Ligands to the androgen receptor are known to play an important role in prostatic hyperplasia, including cancer of the prostate and benign prostatic hypertrophy, male pattern baldness, acne, idiopathic hirsutism, Stein-Leventhal syndrome, mammary cancers and other health care problems. Thus, antagonists to testosterone, the endogenous-hormone of the androgen receptor, are useful in treating chronic disorders such as those described above. In addition, the identification of compounds which interact with the androgen receptor, and thereby affect transcription of genes which are responsive to testosterone, would be of significant value, e.g., for therapeutic applications such as treatment of hormonally-responsive benign and malignant disorders.


Further, the identification of compounds which have good specificity for the androgen receptor, but which have less cross-reactivity for other intracellular receptors,

would be of significant value since interaction of a ligand with other than the target intracellular receptors is known to result in significant undesirable pharmacological side effects. Accordingly, antagonists to the androgen receptor which do not display cross-reactivity with other intracellular receptors (e.g., glucocorticoid receptor and mineralocorticoid receptor) will exhibit an improved therapeutic index.

A group of prenylated bromohydroquinones, called collectively cymopols, has been isolated and identified by several investigators using as a starting material the green marine alga Cymopolia barbata (L.) Lamouroux (Dasycladaceae). Among these, cymopol, $C_{16}H_{21}BrO_2$, is a crystalline phenol which has a bromogeranyl-hydroquinone or brominated monoterpene-quinol structure. As described by Högberg et al., J.C.S. Perkin I, 1696-1701 (1976), cymopol [2-bromo-5-(3,7-dimethylocta-2,6-dienyl) hydroquinone] and its monomethyl ether, $C_{17}H_{23}BrO_2$, have the following structures:




Cymopol



Cymopol monomethyl ether

Cyclocymopol [1-bromo-3-(4-bromo-2,5-dihydroxybenzyl)-2,2-dimethyl-4 methylene cyclohexane] and its monomethyl ether have also been obtained from C. barbata. See Högberg et al., supra. As described in McConnell et al.,
 5 Phytochemistry, Vol. 21, No. 8, pp. 2139-41 (1982), C. barbata contains a mixture of optically active diastereomers of cyclocymopol, $C_{16}H_{20}Br_2O_2$, and cyclocymopol monomethyl ether, $C_{17}H_{22}Br_2O_2$, having the following structures:



1a (R=H): 2a (R=Me): H (C-3)-pseudo-equatorial
 10 1b (R=H): 2b (R=Me): H (C-3)-pseudo-axial
 (The above assumes the equatorial conformation for bromine at C-1).

Through silica gel chromatography of an ether-soluble extract of C. barbata, McConnell et al. were able to
 15 obtain a 1:1 mixture of $\alpha:\beta$ epimers of cyclocymopol. McConnell et al. also obtained a 3:1 mixture of $\alpha:\beta$ epimers of cyclocymopol monomethyl ether, which was enriched to a 4:1 mixture of the $\alpha:\beta$ epimers through purification techniques.

20 Wall et al., J. Nat. Prod., Vol. 52, No. 5, pp. 1092-99 (1989), described additional diastereomeric cymopol compounds (cymobarbatol and 4-isocymobarbatol) which were determined to be highly active antimutagens. Wall et al. reported obtaining pure cymobarbatol compounds, but were
 25 unable to obtain stable cyclocymopol fractions. Apparently, however, the forms of cyclocymopol and

cyclocymopol monomethyl ether obtained by Högberg et al., supra, were pure forms of formulae 1b and 2b above.

The publications and references referred to above and hereafter in this specification are expressly incorporated
5 herein by reference.

Summary of the Invention

The present invention is directed to compounds, compositions, and methods for modulating processes mediated by the androgen receptor. More particularly, the invention
10 relates to non-steroidal compounds which are high affinity, high specificity ligands for the androgen receptor (AR). These compounds exhibit AR antagonist activity, and modulate processes mediated by AR. Accordingly, the invention also relates to methods for modulating processes
15 mediated by AR employing the compounds disclosed. Examples of compounds used in and forming part of the invention include synthetic cyclocymopol analogs, and semi-synthetic derivatives of natural cyclocymopols. Pharmaceutical compositions containing the compounds dis-
20 closed are also within the scope of this invention. Also included are methods for identifying or purifying AR by use of the compounds of this invention.

Definitions

In accordance with the present invention and as used
25 herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.

The term alkyl refers to straight-chain, branched-chain, cyclic structures, and combinations thereof.

The term "aryl" refers to aromatic groups which have
30 at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted, being preferably phenyl or phenyl substituted by one to three substituents, such substituents being advantageously
35 lower alkyl, hydroxy, lower alkoxy, lower acyloxy,

halogen, cyano, trihalomethyl, lower alcyamino, or lower alkoxy carbonyl.

Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and optionally substituted naphthyl groups.

Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and suitable heterocyclic aryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, and the like, all optionally substituted.

The term "aralkyl" refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl and the like, and may be optionally substituted.

The term "lower" referred to herein in connection with organic radicals or compounds respectively defines such with up to and including 7, preferably up to and including 4 and advantageously one or two, carbon atoms. Such groups may be straight chain or branched.

Brief Description of the Drawings

The present invention may be better understood, and its advantages appreciated by those skilled in the art by referring to the accompanying drawings wherein:

Figure 1 presents activation profiles for analysis of androgen receptor by increasing concentrations of dihydrotestosterone (DHT) (•) and the antagonist dose response profile of 2-Hydroxy-flutamide (+) at a constant concentration of 5×10^{-9} M DHT;


Figure 2 presents antagonist activation profiles for analysis of androgen receptor by derivative compound "A" (•) and for derivative compound "B" (+); and

Figure 3 presents antagonist activation profiles for analysis of androgen receptor by derivative compound "B"


(•), derivative compound "C" (+), and derivative compound "D" (*).

Detailed Description of Embodiments of the Invention

Cyclocymopols useful in this invention are defined as
5 those having the formulae:



or



wherein:

the dotted lines in the structure depict optional double bonds;

10 X is carbon, oxygen, or nitrogen;

R₁ is R₁₇, -OR₁₇, -N(R₁₇)(R₁₇), -SR₁₇, fluorine, chlorine, bromine, or -NO₂;

R₁₇, and (R₁₇), each independently, are hydrogen, saturated or unsaturated C₁-C₆ alkyl, C₃-C, cycloalkyl, C₅-C,

aryl, or C₇ aralkyl, said alkyl groups being branched or straight-chain;

R₂ is -NO₂, -N(OH)R₁₇, fluorine, chlorine, bromine, iodine, R₁₇, -N(R₁₇)(R₁₇), -SR₁₇, -S(O)-R₁₇, -S(O)₂-R₁₇, -CH₂OH, -C(O)CH, -C(O)CH₃, -C(O)-OCH₃, -C=CH₂, -C=CH-C(O)-OCH₃, or R₁₈;

R₁₈ and (R₁₈), each independently, are hydrogen, saturated or unsaturated C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₅-C₇ aryl, or C₇ aralkyl, said alkyl groups being branched or straight-chain which optionally may contain hydroxyl, aldehyde, ketone, nitrile, or ester groups;

R₃ is R₁₇ or -OR₁₇;

R₄ is hydrogen, -OR₁₇, -OC(O)R₁₇, -OC(O)OR₁₇, -OC(O)N(R₁₇)(R₁₇), -OS(O)₂R₁₇, or -OS(O)-R₁₇;

R₅ is hydrogen or OR₁₇;

R₆ is R₁₇;

R₇ and R₈, each independently, are R₁₈, or R₇ and R₈ together are a carbocyclic 3-8 member ring;

R₉ and R₁₀, each independently, are chlorine, bromine, or R₁₇, or R₉ and R₁₀, combined are =O, except when X=O, R₉ and R₁₀ are not present, and when X is N, then R₁₀ is not present, or R₉ and R₁₀ together are joined in a carbocyclic 3-8 member ring;

R₁₁ and R₁₂, each independently, are -OR₁₇, R₁₈, are =O, or are =CH₂, except when R₁₁ is attached to an sp² carbon atom in the ring, then R₁₂ is not present and R₁₁ is R₁₈,

or R₁₁ and R₁₃ together are joined in a carbocyclic 3-8 member ring or are -O- to form an epoxide;

R₁₃ and R₁₄, each independently, are -OR₁₇ or R₁₈, except when R₁₃ is attached to an sp² carbon atom in the ring, then R₁₄ is not present and R₁₃ is -OR₁₇ or R₁₈;

R₁₅ and R₁₆, each independently, are R₁₈ or OR₁₇, or R₁₅ and R₁₆ together are -CH₂-O- forming an epoxide, or R₁₅ and R₁₆ combined are =O or =C(R₁₈)(R₁₈), except when R₁₅ is hydroxyl, then R₁₆ is not hydroxyl, and when R₁₅ is attached to an sp² carbon atom in the ring, then R₁₆ is not present,

or R₁₅ and R₁₆ together are joined in a carbocyclic 3-8 member ring.

Representative compounds and derivatives according to the present invention include the following:

- 5 1-Methylidene-6-(3'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene;
 (1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane;
 1-Methylidene-6-(2'-hydroxyphenyl)methyl-5,5-dimethyl-
10 cyclohex-2-ene;
 1-Methylidene-2-(2'-hydroxyphenyl)methyl-5,5-dimethylcyclohexane;
 (4S,6S)-1-Methylidene-4-bromo-5-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene;
15 1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene;
 2-(4'-Nitrophenyl)methylcyclohexan-1-one;
 8-(2'-Acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,7,7-trimethylspiro[2.5]oct-4-ene;
20 trans-2-(4'-Nitrophenyl)methylcyclohexan-1-ol;
 (1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-1,4,4-trimethylcyclohexane;
 1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclopentane;
25 (5R,6S)-1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5-methylcyclohex-2-ene;
 1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane;
 (2R)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane;
30 (5R,6S)-1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-3,5-dimethylcyclohex-2-ene;
 (1R,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-1,4,4-trimethylcyclohexane;
35 trans-1-Methyl-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methylcyclohexan-1-ol;

(1R,3R)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane;
cis-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3,5-trimethylcyclohexane;
5 1-Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene;
1-Methylidene-6-(4'-nitro-3'-methylphenyl)methyl-3,5,5-trimethylcyclohex-2-ene;
2-(4'-Nitrophenyl)methyl-3,3-dimethylcyclohexan-1-one;
10 1-Methylidene-6-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene;
(2S)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane; and
2-(2'-Hydroxy-4'-bromo-5'-methoxyphenyl)methylcyclo-
15 hex-1-one.

Compounds comprising the class of synthetic cyclocymopol analogs and derivatives disclosed herein can be obtained by routine chemical synthesis by those skilled in the art, e.g., by modification of the cyclocymopol
20 compounds disclosed or by a total synthesis approach.

The invention will be further illustrated by reference to the following non-limiting Examples. All parts and percentages are expressed as parts by weight unless otherwise indicated.

25 Example 1

Synthetic and semisynthetic cyclocymopol analogs have been prepared which display antagonist activity for the intracellular receptor for androgen. Representative
30 analogs of the present invention are prepared according to the following illustrative synthetic schemes and illustrative Examples.

Synthesis of Aromatic Subunit

2-Acetoxy-5-methoxybenzaldehyde (1):

To a flame-dried 50 mL round-bottomed flask containing
35 10.00 g (65.7 mmol) 2-hydroxy-5-methoxybenzaldehyde in 10

mL dry pyridine at 0°C under nitrogen atmosphere was added 7 mL acetic anhydride. The reaction mixture was then allowed to warm to room temperature and continually stirred until thin-layer chromatography (TLC) analysis indicated complete consumption of starting material (50 min). Ethyl acetate (150 mL) was added, and the mixture was then transferred to a separatory funnel and successively washed with 1N HCl (3 x 50 mL), saturated aqueous NaHCO₃, (1 x 50 mL), and brine (1 x 50 mL), dried over Na₂SO₄, and concentrated under reduced pressure to give 12.41 g (97%) of the acetylated phenol as a white solid. The product thus obtained was homogenous by TLC (R_f 0.41, 2:1 hexane/ethyl acetate), and was carried on to the next step without further purification.

15 2-Acetoxy-4-bromo-5-methoxybenzaldehyde (2):

To a 500 mL round-bottomed flask containing a solution of 20.0 g (168.1 mmol, 3.26 equiv) potassium bromide and 3.21 mL (10.0 g, 62.6 mmol, 1.21 equiv) bromine in 200 mL water at room temperature was added 10.00 g (51.5 mmol, 1.0 equiv) 2-acetoxy-5-methoxybenzaldehyde (1) as a finely divided white powder, portionwise over a period of 35 min. After 18 h stirring at room temperature, the reaction mixture was filtered under vacuum using a Büchner funnel to give 10.59 g (89%) of the aryl bromide as a pale yellow solid (R_f 0.45, 2:1 hexanes/ethyl acetate). The product thus obtained was of greater than 98% purity by ¹H NMR, and homogenous by TLC, and was carried on to the next step without further purification. A portion of the crude product was recrystallized from 5:1 ether/hexanes to give white needles. ¹H NMR (400 MHz, CDCl₃) δ 2.37 (s, 3H, COCH₃), 3.93 (s, 3H, OCH₃), 7.36 and 7.46 (2s, 2 x 1H, Ar-H), 10.08 ppm (s, 1H, CHO).

2-Hydroxy-4-bromo-5-methoxybenzaldehyde (3):

To a 200 mL round-bottomed flask containing 6.90 g (25.3 mmol) 2 acetoxy-4-bromo-5-methoxybenzaldehyde (2) in

100 mL of 1% aqueous methanol at room temperature was added 5 g K_2CO_3 , and the mixture was allowed to stir at room temperature for 1 h, at which time TLC analysis indicated complete consumption of starting material and the presence of a slightly more polar compound as the only detectable product. The reaction mixture was then neutralized to pH 5 with the addition of 1 N HCl, and the solvent was subsequently removed under diminished pressure. The residue was then dissolved in ethyl acetate (200 mL), washed successively with 1 N HCl (1 x 50 mL), saturated aqueous $NaHCO_3$ (1 x 50 mL), and brine (1 x 50 mL), dried over Na_2SO_4 , and concentrated under diminished pressure to give 4.97 g (85%) of the bromophenol as a brownish-red oily solid. A portion of this crude material was recrystallized from 2:1 hexanes/ethyl acetate to give white needles. 1H NMR (400 MHz, $CDCl_3$) δ 3.89 (s, 3H, OCH_3), 6.97 and 7.27 (2s, 2 x 1H, Ar-H), 9.83 (s, 1H, OH), 10.71 ppm (s, 1H, CHO). The remainder of the material was carried on to the next step without further purification.

20 2-(tert-Butyl)dimethylsilyloxy-4-bromo-5-methoxybenzaldehyde (4):

To a flame-dried 100 mL round-bottomed flask containing 2.76 g (11.95 mmol) 2-hydroxy-4-bromo-5-methoxybenzaldehyde (3) in 50 mL anhydrous dichloromethane under nitrogen atmosphere at room temperature was added 2.03 g (29.88 mmol, 2.50 equiv) imidazole, 2.25 g (14.94 mmol, 1.25 equiv) (tert-butyl)-dimethylchlorosilane, and 4-N,N'-dimethyl propyleneurea (DMAP) (100 mg, catalytic). The mixture was allowed to stir at room temperature for 75 min, at which time TLC analysis indicated complete consumption of starting material, and the formation of a less polar product (R_f 0.75, 2:1 hexanes/ethyl acetate). The reaction mixture was then poured into a separatory funnel containing 50 mL dichloromethane and 50 mL saturated aqueous NH_4Cl , the layers were separated, and the organic phase was washed with 50 mL brine, dried over

Na_2SO_4 , and concentrated under diminished pressure to give 4.13 g (quantitative) of the silylated bromophenol as an off-white solid, a portion of which was recrystallized from 3:1 hexanes/ether to give an amorphous white solid.

5 ^1H NMR (400 MHz, CDCl_3) δ 0.27 [s, 6H, $\text{Si}(\text{CH}_3)_2$], 1.02 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 3.89 (s, 3H, OCH_3), 7.14 (s, 1H, 6-H), 7.28 (s, 1H, 3-H), 10.35 ppm (s, 1H, CHO); ^{13}C NMR (100.61 MHz, CDCl_3) δ -4.4, 18.3, 25.7, 56.6, 108.9, 120.1, 125.6, 126.5, 151.0, 152.9, 189.1 ppm.

10 2-(tert-Butyl)dimethylsilyloxy-4-bromo-5-methoxybenzyl alcohol (5):

To a flame-dried 200 mL round-bottomed flask containing 4.10 g (13.14 mmol) 2-(tert-butyl)dimethylsilyloxy-4-bromo-5-methoxybenzaldehyde (4) in 100 mL anhydrous
15 methanol at 0°C was added 0.50 g (13.15 mmol, 1.0 mol equiv) NaBH_4 over a period of 3 min. After 20 min at 0°C, TLC analysis indicated complete consumption of starting material, and the formation of a more polar product (R_f 0.42, 2:1 hexanes/ethyl acetate). Water (75 mL) was
20 added, and the methanol was removed by rotary evaporation. The resultant aqueous residue was extracted with ethyl acetate (2 x 100 mL), and the combined organic layers were dried over Na_2SO_4 , and concentrated under diminished pressure. Purification by flash column chromatography
25 (silica gel, hexanes/ethyl acetate, 5:1) afforded 4.10 g (98%) of the benzylic alcohol as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 0.23 [s, 6H, $\text{Si}(\text{CH}_3)_2$], 1.00 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 3.86 (s, 3H, OCH_3), 4.61 (s, 2H, CH_2OH), 6.92 (s, 1H, 6-H), 6.97 ppm (s, 1H, 3-H).

30 2-(tert-Butyl)dimethylsilyloxy-4-bromo-5-methoxybenzyl bromide (6):

To a flame-dried 100 mL round-bottomed flask containing triphenylphosphine (1.27 g, 4.84 mmol, 1.05 equiv) in 25 mL anhydrous dimethylformamide (DMF) at 0°C under
35 nitrogen atmosphere was added bromine (0.24 mL, 4.84 mL,

1.05 equiv, plus enough extra to cause a persistent red-dish tint to the solution, 1 drop) through an additional funnel. To this reaction mixture was added 2-(*tert*-butyl)dimethylsilyloxy-4-bromo-5-methoxybenzyl alcohol (5) through the addition funnel at a steady rate over 30 min, as a solution in 10 mL DMF. The reaction mixture was allowed to stir at 0°C for 60 min, at which time TLC analysis indicated complete consumption of starting material, and the formation of a less polar product (*R_f* 0.81, 2:1 hexanes/ethyl acetate). Hexane (100 mL) was then added, and the contents of the flask were transferred to a separatory funnel containing 50 mL of saturated aqueous NH_4Cl , rinsing with an additional 50 mL hexane and 10 mL water. The layers were separated, and the organic phase was washed with 20 mL 10% $\text{Na}_2\text{S}_2\text{O}_3$, dried over Na_2SO_4 , and concentrated under diminished pressure. Purification by trituration at 0°C (2 x 30 mL ea. hexanes) to remove residual triphenylphosphine oxide, followed by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 1.51 g (80%) of the benzylic bromide as a colorless, viscous oil, which solidified upon standing. ^1H NMR (400 MHz, CDCl_3) δ 0.27 [s, 6H, $\text{Si}(\text{CH}_3)_2$], 1.04 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 3.84 (s, 3H, OCH_3), 4.46 (s, 2H CH_2Br), 6.87 and 7.01 ppm (2s, 2 x 1H, Ar-H).

25 2-(*tert*-Butyl)dimethylsilyloxybenzaldehyde (7):

This compound was prepared from salicylaldehyde (3.00 g, 24.1 mmol) in the manner previously described for the synthesis of silyl ether (4), affording 4.23 g (74%) of the silylated phenol as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 0.28 [s, 6H, $\text{Si}(\text{CH}_3)_2$], 1.03 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 6.88 (d, 1H, J = 8.5 Hz, Ar-H), 7.03 (dd, 1H, J = 7.4 Hz, Ar-H), 7.46 (ddd, 1H, J = 8.6, 7.4, 2.0 Hz, Ar-H), 7.81 (dd, 1H, J = 7.7, 1.9 Hz, Ar-H), 10.47 ppm (s, 1H, CHO).


2-(tert-Butyl)dimethylsilyloxybenzyl alcohol (8):

This compound was prepared from 2-(tert-butyl)dimethylsilyloxybenzaldehyde (7) (4.23 g, 17.9 mmol) in the manner previously described for the synthesis of benzyl alcohol 5, affording 2.81 g (66%) of the silyloxybenzyl alcohol as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 0.26 [s, 6H, Si(CH₃)₂], 1.02 [s, 9H, SiC(CH₃)₃], 4.68 (d, 2H, J = 6.3 Hz, CH₂OH), 6.81 (d, 1H, J = 6.3 Hz, Ar-H), 6.95 (dd, 1H, J = 7.1, 7.1 Hz, Ar-H), 7.17 (ddd, 1H, J = 9.5, 7.8, 1.7 Hz, Ar-H), 7.30 ppm (dd, 1H, J = 5.8, 1.6 Hz, Ar-H).


2-(tert-Butyl)dimethylsilyloxybenzyl bromide (9):

This compound was prepared from 2-(tert-butyl)dimethylsilyloxybenzyl alcohol (8) (2.81 g, 11.8 mmol) in the manner previously described for the synthesis of benzyl bromide 6, affording 1.14 g (32%) of the silyloxybenzyl bromide as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.30 [s, 6H, Si(CH₃)₂], 1.07 [s, 9H, SiC(CH₃)₃], 4.54 (s, 2H, CH₂Br), 6.83 (d, 1H, J = 6.2 Hz, Ar-H), 6.93 (dd, 1H, J = 7.1, 7.1 Hz, Ar-H), 7.19 (ddd, 1H, J = 9.4, 7.9, 1.6 Hz, Ar-H), 7.34 ppm (dd, 1 H, J = 5.8, 1.6 Hz, Ar-H).

17





18

Example 2Synthesis of Aliphatic Subunits3-Ethoxy-5,5-dimethylcyclohex-2-en-1-one (10):

To a flame-dried 1 L round-bottomed flask containing
 5 15.0 g (107 mmol) 5,5-dimethylcyclohexane-1,3-dione and
 120 mL absolute ethanol in 300 mL anhydrous benzene under
 nitrogen atmosphere was added 750 mg p-toluenesulphonic
 acid monohydrate (catalytic). The flask was fitted with
 a Dean Stark trap for removal of water, and a reflux
 10 condenser, and the mixture was heated to reflux for 9 h.
 Upon cooling to room temperature, the solvent was removed
 by rotary evaporation, and the residue was dissolved in
 300 mL ethyl acetate. The organic solution was then
 washed successively with 10% aqueous NaOH (2 x 100 mL),
 15 water (1 x 100 mL), and brine (1 x 100 mL), dried over
 Na₂SO₄, and concentrated under diminished pressure to give
 16.5 g (92%) of the keto-enol ether as a pale yellow oil
 (R_f 0.24, 2:1 hexanes/ethyl acetate) of greater than 98%
 purity by ¹H NMR. ¹H NMR (400 MHz, CDCl₃) δ 1.08 (s, 6H,
 20 geminal-CH₃'s), 1.38 (dd, 3H, OCH₂CH₃), 2.21 and 2.28 (2s,
 2 x 2H, 6-H, 4-H), 3.90 (q, 2H, OCH₂CH₃), 5.32 ppm (s, 1H,
 2-H).

5,5-Dimethylcyclohex-2-en-1-one (11):

To a flame-dried 100 mL round-bottomed flask containing lithium aluminum hydride (0.95 g, 24.4 mmol, 0.5 mol equiv) in 35 mL anhydrous ether under nitrogen atmosphere at 0°C was added 8.20 g (48.7 mmol) 3-ethoxy-5,5-dimethylcyclohex-2-en-1-one (10) portionwise through a syringe as a solution in 10 mL anhydrous ether. The reaction mixture was allowed to warm to room temperature, and after 4h, TLC analysis indicated complete consumption of starting material. The reaction mixture was then cooled to 0°C before the cautious addition of 50 mL water, and the contents of the flask were then poured into a 500 mL Erlenmeyer flask containing 150 mL ice-cold 10% H₂SO₄. The mixture was then extracted with ether (2 x 200 mL), and the combined organics were washed successively with water (100 mL), and saturated aqueous NaHCO₃ (100 mL), dried over Na₂SO₄, and concentrated under diminished pressure to give 6.05 g (quantitative) of the dimethylenone (R_f 0.55, 2:1 hexane/ethyl acetate). ¹H NMR (400 MHz, CDCl₃) δ 1.05 (s, 6H, geminal-CH₃'s), 2.23 (dd, 2H, 4-H), 2.28 (s, 2H, 6-H), 6.03 (ddd, 1H, 2-H), 6.87 ppm (ddd, 1H, 3-H).



Synthesis of AnalogsExample 3

6-[2'-(tert-Butyl)dimethylsilyloxy-4'-bromo-5'-methoxy-phenyl]methyl-5,5-dimethylcyclohex-2-en-1-one (13):

5 To a flame-dried 50 mL round-bottomed flask containing diisopropylamine (0.188 mL, 1.34 mmol, 1.1 equiv) in 10 mL anhydrous tetrahydrofuran (THF) at -78°C under nitrogen atmosphere was added *n*-butyllithium (0.58 mL of a 2.2 M solution in hexanes, 1.28 mmol, 1.05 equiv). After 20 min
10 at -78°C, 5,5-dimethylcyclohex-2-en-one (11) (0.151 g, 1.22 mmol) was added as a solution in 1 mL of THF, and the reaction mixture was allowed to stir at that temperature for 15 min, at which time the cooling bath was removed. When the temperature of the reaction mixture (monitored
15 using a thermocouple probe) reached -5°C, 2-(tert-butyl)dimethylsilyloxy-4-bromo-5-methoxybenzyl bromide (6) (1.00 g, 2.44 mmol, 2.0 equiv) was added all at once as a solution in 2 mL THF. The reaction mixture was then allowed to warm to room temperature, and after 3 h, TLC analysis
20 indicated complete consumption of the enone starting material, and the formation of a product of intermediate polarity with respect to the two starting components (Rf 0.59, 2:1 hexanes/ethyl acetate), and the reaction was quenched by the addition of 5 mL saturated aqueous NH₄Cl.
25 The contents of the flask were transferred to a separatory funnel, and extracted with 60 mL ethyl acetate, and the resultant organic phase was washed with 30 mL brine, dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel,
30 hexanes/ethyl acetate gradient elution) afforded 0.459 g (83%) of the benzylated enone as a colorless, viscous oil, which solidified on standing. ¹H NMR (400 MHz, CDCl₃) δ 0.21 and 0.23 [2s, 2 x 3H, Si(CH₃)₂], 1.00 [s, 9H, SiC(CH₃)₃], 1.02 and 1.03 (2s, 2 x 3H, geminal-CH₃'s), 2.25 an 2.32 (ddd of ABq, 2H, 4-H), 2.51 (dd, 1H, 6-H), 2.78 and 2.88 (d of ABq, 2H, benzylic-CH₂), 3.80 (s, 3H, OCH₃),

5.96 (ddd, 1H, 2-H), 6.68 (s, 1H, 6'-H), 6.77 (ddd, 1H, 3-H), 6.94 ppm (s, 1H, 3'-H).

2-[2'-(tert-Butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-3,3-dimethyl-cyclohexanone (14):

5 To a flame-dried round-bottomed flask containing 6-[2'-(tert-butyl) dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-5,5-dimethylcyclohex-2-en-1-one (13) (0.154 g, 0.454 mmol) in 22 mL ethyl acetate (which had been pre-dried over K_2CO_3) at room temperature was added 20 mg 5%
10 palladium on carbon, and after flushing/evacuating the vessel 3 times with nitrogen, a hydrogen atmosphere was introduced and maintained by use of a balloon. After 24 h, the flask was again flushed several times with nitrogen, and the contents of the flask were filtered, rinsing
15 with an additional 100 mL ethyl acetate. Rotary evaporation of the solvent afforded 0.156 g (quantitative) of the saturated benzylic ketone as a colorless, viscous oil (Rf 0.67, 2:1 hexanes/ethyl acetate). 1H NMR (400 MHz, $CDCl_3$) δ 0.22 and 0.25 [2s, 2 x 3H, Si(CH₃)₂], 0.87 and 1.12 (2s, 2 x 3H, geminal-CH₃'s), 1.01 [s, 9H, SiC(CH₃)₃], 3.71 (s, 20 2 x 3H, OCH₃), 6.79 (s, 1H, 6'-H), 6.91 ppm (s, 1H, 3'-H).

1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane (16):

To a flame-dried 50 mL round-bottomed flask containing
25 2-[2'-(tert-butyl) dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-3,3-dimethylcyclohexanone (14) (0.130 g, 0.28 mmol) in 5 mL anhydrous THF at -78°C under nitrogen atmosphere was added (trimethyl)silylmethylolithium (0.420 mL of a 1.0 M solution in pentane, 0.42 mmol, 1.50 equiv).
30 An immediate change from colorless to a yellow reaction solution was observed, and TLC analysis at that time indicated complete consumption of starting material, and the formation of a less polar product (Rf 0.79, 2:1 hexanes/ethyl acetate), and the reaction was subsequently
35 quenched with 4 mL saturated aqueous NH_4Cl . Ethyl acetate

(30 mL) extraction of the reaction mixture, drying over Na_2SO_4 , and concentration under diminished pressure gave 0.152 g (quantitative) of a crude product (15), which appeared to be a single diastereomer of the ketone addition product by ^1H NMR analysis. A portion of this crude intermediate (0.015 g, 0.028 mmol) was placed in a 10 mL Nalgene vial containing 2 mL THF, 0.2 mL of a premade HF pyridine complex was added, and the mixture was allowed to stir at room temperature for 32 h, at which time TLC analysis indicated complete consumption of starting material, and formation of a more polar product, having passed through a most polar intermediate (confirmed as the desilylated phenol by ^1H NMR). The contents of the reaction vessel were transferred to a separatory funnel containing 20 mL ethyl acetate and 10 mL 1.0 M NaHSO_4 . The layers were separated, and the resultant organic phase was washed with 10 mL brine, dried over Na_2SO_4 , and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 8.7 mg (92%) of the phenolic olefin as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 0.97 and 1.00 (2s, 2 x 3H, geminal- CH_3 's), 2.65 and 2.80 (d of ABq, $J_{\text{AB}} = 14.1$ Hz, $J_{\text{A}} = 10.9$ Hz, $J_{\text{B}} = 3.5$ Hz, 2H, benzylic- CH_2), 3.80 (s, 3H, OCH_3), 4.36 (d, 1H, $J = 1.0$ Hz) and 4.64 (s, 1H) [methylidene- CH_2], 6.59 (s, 1H, 6'-H), 6.94 ppm (s, 1H, 3'-H); ^{13}C NMR (100.61 MHz, CDCl_3) δ 23.5, 26.7, 28.1, 28.4, 32.4, 35.2, 36.1, 54.3, 57.0, 108.3, 110.3, 115.0, 120.1, 128.8, 148.0, 148.5, 150.0 ppm. [Compound 16 is hereinafter also referred to as COMPOUND "M" or 120019]

30 Examples 4-5

1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclo-hex-2-ene (17):

This compound was prepared from 6-[2'-(tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-5,5-dimethylcyclohex-2-en-1-one (13) (0.075 g, 0.166 mmol) in the manner previously described for olefin 16, with the

following procedural changes necessitated by the incompatibility of structural features particular to this substrate and the typical synthetic methodology. Upon formation of the initial (trimethyl)silylmethylolithium

5 addition adduct to enone 13, the phenolic protecting group was exchanged prior to effecting elimination, using the following protocol adhered to for all cyclocymopol analogs incorporating the methylenediolefin into a 1,3-diene moiety. The crude addition product (0.090 g, 0.166 mmol)

10 was dissolved in 5 mL anhydrous THF containing 0.20 mL acetic anhydride (large excess), and cooled to 0°C under nitrogen atmosphere. Tetra-(n-butyl)ammonium fluoride (0.20 mL of a 1.0 M solution in THF, 0.20 mmol, 1.20 equiv) was added, and the mixture was allowed to warm to

15 room temperature. The contents of the flask were then poured into a separatory funnel containing 30 mL ethyl acetate and 10 mL 1.0 M NaHSO₄, the layers were separated, and the organic phase was washed with 10 mL brine, dried over Na₂SO₄, and concentrated under diminished pressure.

20 The crude material thus obtained was immediately carried on to the next step by transferring to a 10 mL Nalgene vial containing 2-3 mL THF, and 0.3 mL premade HF/pyridine complex was added. After stirring overnight at room temperature, the reaction mixture was worked up in the


25 usual manner, and purification by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 38.3 mg (64%) of the desired acetoxydiene as a colorless, oily solid. ¹H NMR (400 MHz, CDCl₃) δ 0.73 and 1.11 (2s, 2 x 3H, geminal-CH₃'s), 2.27 (s, 3H, acetate-CH₃); 3.83 (s, 3H, OCH₃), 4.13 and 4.68 (2s, 2 x 1H, methylenediolefin-CH₂), 5.70 and 6.04 (2dd, 2 x 1H, 2-H, 3-H), 6.52 (s, 1H, 6'-H), 7.19 ppm (s, 1H, 3'-H). [Compound 17 is hereinafter also referred to as COMPOUND "F" or

30 102032]

1-Methylidene-6-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)
methyl-5,5-dimethylcyclo-hex-2-ene (18):

In a 10 mL test tube was combined 1-methylidene-6-(2'-
acetox-5
y-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethyl-
cyclohexene (17) (10.0 mg, 0.026 mmol) and 2.0 mL of 5%
methanolic K₂CO₃. After 10 min at room temperature, the
methanol was removed by rotary evaporation, and the
resultant residue was dissolved in 20 mL ethyl acetate.
The organic solution was then washed with saturated
10 aqueous NH₄Cl, dried over Na₂SO₄, and concentrated under
diminished pressure. Purification by flash column chroma-
tography (silica gel deactivated with triethylamine,
hexanes/ethyl acetate, gradient elution) afforded 7.1 mg
(81%) of the phenolic diene as a colorless, oily solid.
15 ¹H NMR (400 MHz, CDCl₃) δ 0.73 and 1.16 (2s, 2 x 3H,
geminal-CH₃'s), 3.82 (s, 3H, OCH₃), 4.23 and 4.72 (2s, 2 x
1H, methylidene-CH₂), 5.78 and 6.08 (2dd, 2 x 1H, 2-H, 3-
H), 6.51 (s, 1H, 6'-H), 6.99 ppm (s, 1H, 3'-H). [Compound
18 is hereinafter also referred to as COMPOUND "W" or
20 120033]

25

**Example 6**

6-[2'-(*tert*-Butyl)dimethylsilyloxy-4'-bromo-5'-methoxy-phenyl]methyl-3,5,5-trimethyl-cyclohex-2-en-1-one (19):

This compound was prepared from isophorone (0.168 g, 1.22 mmol) in the manner previously described for enone 13, affording 0.342 g (60%) of the alkylation product (Rf 0.40, 2:1 hexanes/ethyl acetate) as a colorless, oily

solid. ^1H NMR (400 MHz, CDCl_3) δ 0.20 and 0.22 [2s, 2 x 3H, $\text{Si}(\text{CH}_3)_2$], 0.99 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 1.00 and 1.02 (2s, 2 x 3H, geminal- CH_3 's), 1.91 (s, 3H, 3- CH_3), 2.18 and 2.28 (ABq, 2H), 2.42 (dd, 1H), 2.82 (dd, 2H), 3.70 (s, 3H, OCH₃), 5.82 (sl d, 1H, 2-H), 6.71 (s, 1H, 6'-H), 6.92 ppm (s, 1H, 3'-H).

1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-3,5,5-trimethylcyclohex-2-ene (20):

This compound was prepared from 6-[2'-(tert-butyl) dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-3,5,5-trimethylcyclohex-2-en-1-one (19) (42.0 mg, 0.090 mmol) in the manner previously described for acetoxy diene 17, affording 18.4 mg (52%) of the acetoxy-diene as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 0.87 and 1.11 (2s, 2 x 3H, geminal- CH_3 's), 1.78 (s, 3H, 3- CH_3), 2.26 (s, 3H, acetate- CH_3), 3.83 (s, 3H, OCH₃), 4.03 and 4.58 (2s, 2 x 1H, methylidene- CH_2), 5.82 (s, 1H, 2-H), 6.52 (s, 1H, 6'-H), 7.19 ppm (s, 1H, 3'-H).

8-(2'-Acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,7,7-trimethylspiro[2,5]oct-4-ene (21):

To a flame-dried 10 mL round-bottomed flask containing 20.0 mg (0.051 mmol) 1-methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-3,5,5-trimethylcyclohex-2-ene (20) in 1 mL 1,2-dichloroethane under nitrogen atmosphere at 0°C was added diethylzinc (254 μL of a 1.0 M solution in hexanes, 0.255 mmol, 5.0 equiv). Chloriodomethane (37 μL , 0.510 mmol, 10.0 equiv) was added dropwise, and the mixture was allowed to warm to room temperature. After 9 h, the reaction mixture was quenched at 0°C with saturated aqueous NH_4Cl , and the reaction mixture was extracted with ethyl acetate (50 mL). The organic phase was washed with brine (20 mL), dried over Na_2SO_4 , and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 20 mg (96%) of the spirocyclopropane as

a colorless, viscous oil. ^1H NMR (400 MHz, CDCl_3) δ -0.07 (ddd, 1H, J = 11.0, 9.3, 5.9 Hz, cyclopropyl-H), 0.16 (ddd, 1H, J = 11.5, 9.4, 6.1 Hz, cyclopropyl-H), 0.32 (ddd, 1H, J = 10.1, 5.8, 5.8 Hz, cyclopropyl-H), 0.43
5 (ddd, 1H, J = 9.8, 6.1, 6.1 Hz, cyclopropyl-H), 1.03 and 1.06 (2s, 2 x 3H, geminal- CH_3 's), 1.60 and 1.98 (ABq, 2H, J_{AB} = 17.8 Hz, 6-H), 1.69 (s, 3H, 5- CH_3), 2.25 (s, 3H, acetate- CH_3), 2.39 and 2.65 (d of ABq, 2H, J_{AB} = 13.6 Hz, J_{A} = 10.0 Hz, J_{B} = 3.4 Hz, benzylic- CH_2), 3.86 (s, 3H, 10 OCH_3), 4.68 (s, 4-H), 6.69 (s, 1H, 6'-H), 7.18 ppm (s, 1H, 3'-H). [Compound 21 is hereinafter also referred to as COMPOUND "H" or 120299]

Example 7

cis-2-[(2'-tert-Butyl)dimethylsilyloxy-4'-bromo-5'-
15 methoxyphenyl]methyl-3,3,5-trimethylcyclohexan-1-one (22).


To a suspension of copper(I) iodide (2 mg) in 1 mL of anhydrous ether at 0°C was added methylmagnesium bromide (0.106 mL of a 3.0 M solution in ether, 0.319 mmol, 1.00 equiv). Then enone 13 (149 mg, 0.319 mmol) in 2 mL of
20 anhydrous ether was added slowly to the stirring cuprate mixture at a temperature maintained below 5°C, and upon completion of the addition, the reaction mixture was stirred at 0°C for 3 h before quenching with a 4:1 mixture of saturated aqueous $\text{NH}_4\text{Cl}/\text{NH}_4\text{OH}$. The resultant biphasic
25 mixture was extracted with ether, dried over Na_2SO_4 , and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 9:1) afforded 36 mg (30%) of the desired conjugate addition product as a white solid. ^1H NMR (400 MHz,
30 CDCl_3) δ 0.22 (s, 6H, $\text{Si}(\text{CH}_3)_2$), 1.00 [m, 18H, 3,3,5- CH_3 and $\text{SiC}(\text{CH}_3)_3$], 1.50 (dd, 2H, J = 15.1, 6.5 Hz, 4-H), 2.02 (m, 1H, 5-H), 2.14 and 2.23 (ABq, 2H, J_{AB} = 12.0 Hz, 6-H), 2.42 (dd, 1H, J = 10.4, 6.4 Hz, 2-H), 2.88 and 2.89 (d of ABq, 2H, J_{AB} = 12.0 Hz, J_{A} = 10.4 Hz, J_{B} = 6.3 Hz, benzylic- CH_2),
35 3.82 (s, 3H, OCH_3), 6.65 (s, 1H, 6'-H), 6.92 ppm (s, 1H, 3'-H).

cis-1-Methyldiene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)-methyl-3,3,5-trimethyl-cyclohexane (23):

To a solution of cis-2-[(2'-tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-3,3,5-trimethylcyclohexan-1-one (22) (7.5 mg, 0.016 mmol, 1.0 equiv) in 1 mL of anhydrous THF at -78°C was added (trimethyl)silylmethylolithium (66 µL of a 1.0 M solution in pentane, 0.066 mmol, 4.0 equiv) and the mixture was stirred for 20 min, at which time TLC analysis indicated complete consumption of starting material, and the reaction was quenched at -78°C with 1 mL of saturated aqueous NH₄Cl solution. The resulting biphasic mixture was allowed to warm to room temperature and was extracted with ethyl acetate (30 mL), and the organic layer was dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 4:1) afforded 7.3 mg (86%) of the desired tertiary alcohol intermediate as a colorless oil. Five milligrams of this intermediate were placed in a 10 mL Nalgene vial containing 1 mL of dry THF, 68 µL of HF/pyridine complex were added, and the mixture was allowed to stir at room temperature for 32 h, after which time the contents of the vial were transferred into a separatory funnel containing 3 mL of ethyl acetate and 1 mL of 1 M aqueous NaHSO₄. The layers were separated, and the organic phase was washed with 1 mL of brine, dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 9:1) afforded 2.7 mg (81 %) of the desired phenol as a colorless, viscous oil. ¹H NMR (400 MHz, CDCl₃) δ 0.92 and 1.06 (2s, 2 x 3H, geminal-CH₃'s), 0.95 (d, 3H, J = 8.0 Hz, 5-CH₃), 1.70 (m, 1H), 1.84 (m, 2H), 2.09 (m, 1H), 2.10 (dd, 1H, J = 13.3, 4.2 Hz, 2-H), 2.58 and 2.81 (d of ABq, 2H, J_{AB} = 13.6 Hz, J_A = 11.2 Hz, J_B = 3.7 Hz, benzylic-CH₂), 3.81 (s, 3H, OCH₃), 4.27 and 4.58 (2s, 2 x 1H, methyldiene-CH₂), 4.42 (s, 1H, OH), 6.53

29

(s, 1H, 6'-H), 6.94 ppm (s, 1H, 3'-H). [Compound 23 is hereinafter also referred to as COMPOUND "S" or 120275]



Example 81-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclo-pentane (26):

This compound was prepared from 4,4-dimethylcyclopent-
5 2-en-1-one (24) and benzylic bromide 6 in 5 steps in the
manner previously described for the synthesis of olefin
16, with the following procedural changes in the last two
steps, from intermediate 25. To a flame-dried 25 mL
round-bottomed flask containing a magnetic stir bar was
10 added 340 mg (0.90 mmol) of cerium trichloride hepta-
hydrate, and the flask was heated to 140°C under vacuum
for 2 h, after which time the solid was cooled to room
temperature, and 3 mL of anhydrous THF was added. After
stirring for 2 h at room temperature, the slurry was
15 cooled to -78°C and (trimethyl) silylmethyl lithium (0.78
mL of a 1.0 M solution in pentane, 0.78 mmol) was added.
After 30 min, 2-[(2'-tert-butyl)dimethylsilyloxy-4'-bromo-
5'-methoxyphenylmethyl-3,3-dimethylcyclopentanone 25
(15.0 mg, 0.034 mmol) in 1 mL of anhydrous THF was added,
20 and the mixture was allowed to stir at -78°C for 4 h,
before quenching with saturated aqueous NH₄Cl. The reac-
tion mixture was extracted with ether, and the organic
phase was dried over Na₂SO₄, and concentrated under
diminished pressure. Purification by flash column
25 chromatography (silica gel, hexanes/ethyl acetate 9:1)
gave 15 mg (83%) of the tertiary alcohol intermediate as
a colorless oil. Compound 26 was prepared from this
alcohol intermediate (7.3 mg, 0.014 mmol) in the manner
previously described for the preparation of olefin 16,
30 affording 3.0 mg (66%) of the desired product as a
colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.92 and 0.96 (2s,
2 x 3H, geminal-CH₃'s), 1.53 (m, 2H, 4-H), 2.39 (m, 3H, 2-H
and 5-H), 2.57 and 2.67 (d of ABq, 2H, benzylic-CH₂), 3.81
(s, 3H, OCH₃), 4.50 (s, 1H, OH), 4.66 and 4.84 (2s, 2 x 1H,
35 methylidene-CH₂), 6.74 (s, 1H, 6'-H), 6.99 ppm (s, 1H, 3'-
H). [Compound 26 is hereinafter also referred to as
COMPOUND "K" or 120192]

Example 92-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methylcyclohex-1-one (28):

This compound was prepared in two steps from cyclo-
5 hexanone and 2-(tert-butyl)dimethylsilyloxy-4-bromo-5-methoxybenzyl bromide (6) as previously described, to give the desired olefin in two steps in 50.4% overall yield as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 2.49 (dd, 1H, 2H), 2.54 and 2.92 (d of ABq, 2H, benzylic-CH₂), 3.83 (s,
10 3H, OCH₃), 4.46 (s, 1H, OH), 6.61 (s, 1H, 6'-H), 7.02 ppm (s, 1H, 3'-H). [Compound 28 is hereinafter also referred to as COMPOUND "Y" or 120125]

Examples 10-11(5R,6S)-6-[2'-(tert-Butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl)methyl-5-methylcyclohex-2-en-1-one (29):

To a solution of lithium diisopropylamide (4.65 mL of a 2.0 M solution in THF, 9.30 mmol, 2.2 equiv) in 15 mL of anhydrous THF and 4.4 mL of dry hexamethylphosphoramide (HMPA) at -35°C was added dropwise ketosulfoxide 12 (pre-
20 pared from (R)-(+)-pulegone according to the method of Oppolzer and Petrzika; *Helv. Chim. Acta* 1978, 61, 2755) in 5 mL of dry THF. The reaction mixture was stirred at -35°C for 3 h, after which 2-(tert-butyl)dimethylsilyloxy-4-bromo-5-methoxybenzyl bromide (6) was added dropwise as
25 a solution in 10 mL of anhydrous THF. The reaction mixture was allowed to stir for an additional 2 h at -35°C, quenched with 1M aqueous NaHSO₄ (15 mL) and extracted with ether (50 mL). The organic layer was washed with water (3 x 15mL) and brine (1 x 15 mL), then dried over Na₂SO₄ and
30 concentrated under diminished pressure to afford 2.37g of the intermediate ketosulfoxide as a pale yellow oil, which was used directly in the next step without purification. A solution of the intermediate ketosulfoxide (2.37 g, 4.20 mmol) and CaCO₃ (0.40 g, 3.90 mmol) in 90 mL of carbon
35 tetrachloride was brought to reflux for 3 h. Upon cooling to room temperature, the reaction mixture was filtered and

the solvent was removed under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 95:5) afforded 550 mg (30%) of the desired enone. ^1H NMR (400 MHz, CDCl_3) δ 0.18 and 0.22 [2s, 2 x 3H, $\text{Si}(\text{CH}_3)_2$], 1.03 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 1.05 (d, 3H, $J = 8.0$ Hz, 5- CH_3), 2.07 (m, 2H), 2.50 (m, 1H, 6-H), 2.65 (m, 1H), 2.91 (m, 2H, benzylic- CH_2), 3.80 (s, 3H, OCH_3), 6.02 (d, 1H, $J = 9.4$ Hz, 2-H), 6.70 (s, 1H, 6'-H), 6.85 (ddd, 1H, $J = 9.6, 4.1, 3.2$ Hz, 3-H), 6.98 ppm (s, 1H, 3'-H).

(5R,6S)-1-Methylenidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5-methylcyclohex-2-ene (30):

To a solution of (5R,6S)-6-[(2'-tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl)methyl-5-methylcyclohex-2-en-1-one (29) (63 mg, 0.139 mmol, 1.00 equiv) in 2 mL of anhydrous THF at -78°C was added (trimethyl)silylmethylolithium (222 μL of a 1.0 M solution in pentane, 0.222 mmol, 1.60 equiv). After 10 minutes of stirring at -78°C , the reaction was quenched at -78°C with 1 mL of saturated aqueous NH_4Cl . The reaction mixture was extracted with ethyl acetate, dried over Na_2SO_4 and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 95:5) afforded 40.5 mg (60%) of the desired tertiary alcohol intermediate, along with 14 mg (22%) of unreacted starting material. This intermediate alcohol (14 mg, 0.028 mmol) was dissolved in 1 mL of anhydrous THF containing 60 mL (0.56 mmol, 20.0 equiv) of acetic anhydride, and cooled to 0°C . Tetra-(n-butyl)ammonium fluoride (33 μL of a 1.0 M solution in THF, 0.033 mmol, 1.20 equiv) was added, and the mixture was allowed to warm to room temperature. The contents of the flask were then poured into a separatory funnel containing 5 mL of ethyl acetate and 2 mL of aqueous 1 M NaHSO_4 . The layers were separated, the organic phase was dried over Na_2SO_4 , and the solvent was removed under diminished pressure. The crude

intermediate (12.4 mg) was placed in a 10 mL Nalgene vial containing 2 mL of dry THF, 0.175 mL of premade HF/pyridine complex was added, and the mixture was allowed to stir at room temperature for 18 h. The contents of the vial were then transferred into a separatory funnel containing 5 mL of ethyl acetate and 3 mL of aqueous 1 M NaHSO₄. The layers were separated, and the organic phase was washed with 2 mL of brine, dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 85:15) afforded 6.4 mg (60% for the 2 steps) of the desired acetylated phenol. ¹H NMR (400 MHz, CDCl₃) δ 0.85 (d, 3H, 5-CH₃), 1.67 (m, 2H), 1.76 (s, 3H, 3-CH₃), 2.20 (dd, 1H), 2.27 (s, 3H, acetate-CH₃), 2.49 (m, 3H), 3.86 (s, 3H, OCH₃), 4.40 and 4.71 (2s, 2 x 1H, methylenedichloride-CH₂), 5.86 (s, 1H, 3-H), 6.64 (s, 1H, 6'-H), 7.21 ppm (s, 1H, 3'-H). [Compound 30 is hereinafter also referred to as COMPOUND "L" or 120260]

(5R,6S)-6-[2'-(tert-Butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl)methyl-3,5-dimethylcyclohex-2-en-1-one (31):


To a suspension of copper(I) iodide (1.36 mg) in 0.5 mL of anhydrous ether at 0°C was added methylmagnesium bromide (222 μL of a 310 M solution in ether, 0.665 mmol, 1.00 equiv), causing the solution to turn dark. A solution of enone (29) (310 mg, 0.665 mmol) in 1 mL of anhydrous ether was added over a period of 2 minutes keeping the temperature below 5°C. After the addition was complete, the mixture was stirred at 0°C for an additional 30 minutes, at which time phenylselenenyl bromide (157 mg, 0.665 mmol) in 0.5 mL of anhydrous THF was added, keeping the temperature below 10°C. The resulting mixture was stirred for 10 minutes, poured into water (2 mL) and extracted with ether (5 mL). The organic phase was washed twice with water (2 mL), dried over Na₂SO₄ and concentrated under diminished pressure. The resultant oil was dissolved in 2 mL of dry dichloromethane and 162

μL of pyridine, and to this a solution of hydrogen peroxide 35% (181 μL) in 162 mL of water was added dropwise, keeping the temperature between 30-35°C and warming if necessary to initiate the reaction. The mixture was stirred at room temperature for 30 minutes, and then poured into a separatory funnel containing dichloromethane-saturated aqueous NaHCO_3 . After extraction of the mixture with dichloromethane, the organic solution was washed successively with 10% aqueous HCl and brine, and dried over Na_2SO_4 . The solvent was removed under diminished pressure, and the residue was purified by flash column chromatography (silica gel, hexanes/ethyl acetate, 9:1), affording 157 mg (60%) of the desired enone as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 0.15 and 0.20 [2s, 2 x 3H, $\text{Si}(\text{CH}_3)_2$], 0.97 [s, 9H, $\text{SiC}(\text{CH}_3)_3$], 0.95 (d, 3H, $J = 8.0$ Hz, 5- CH_3), 1.90 (s, 3H, 3- CH_3), 1.95 (m, 2H), 2.38 (m, 1H), 2.59 (m, 1H, 6-H), 2.87 (m, 2H, benzylic- CH_2), 3.79 (s, 3H, OCH_3), 5.86 (s, 1H, 2-H), 6.69 (s, 1H, 6'-H), 6.96 ppm (s, 1H, 3'-H).

20 (5R,6S)-1-Methyldiene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-3,5-dimethyl-cyclohex-2-ene (32):

To a solution of (5R,6S)-6-[2'-(tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl)methyl-3,5-dimethyl-cyclohex-2-en-1-one (31) (63 mg, 0.139 mmol, 1.0 equiv) in 2 mL of anhydrous THF at -78°C was added (trimethyl)silylmethyl lithium (222 μL of a 1.0 M solution in pentane, 0.222 mmol, 1.60 equiv). After 10 minutes of stirring at -78°C, the reaction was quenched at -78°C with 1 mL of saturated aqueous NH_4Cl . The reaction mixture was extracted with ethyl acetate, dried over Na_2SO_4 , and the solvent was removed under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 95:5), afforded 40.5 mg (60%) of the desired tertiary alcohol intermediate, along with 14 mg (22%) of unreacted starting material. This intermediate alcohol (14 mg, 0.028 mmol) was dissolved in 1 mL of

anhydrous THF containing 60 μ L (0.56 mmol, 20.0 equiv) of acetic anhydride and cooled to 0°C. Tetra-(n-butyl) ammonium fluoride (33 μ L of a 1.0 M solution in THF, 0.033 mmol, 1.2 equiv) was added, and the mixture was allowed to
5 warm to room temperature. The contents of the flask were poured into a separatory funnel containing 5 mL of ethyl acetate and 2 mL of aqueous 1 M NaHSO₄. The layers were separated, and the organic phase was dried over Na₂SO₄. The solvent was removed under diminished pressure, and the
10 crude intermediate (12.4 mg) was placed in a 10 mL Nalgene vial containing 2 mL of dry THF, 0.175 mL of HF/pyridine complex was added, and the mixture was allowed to stir at room temperature for 18 h. The contents of the vial were transferred to a separatory funnel containing 5 mL of
15 ethyl acetate and 3 mL of 1 M aqueous NaHSO₄, the layers were separated, and the organic phase was washed with 2 mL of brine, dried over Na₂SO₄, and the solvent was removed under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 85:15)
20 afforded 6.4 mg (60% for 2 steps) of the desired acetylated phenol as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.85 (d, 3H, 5-CH₃), 1.67 (m, 2H), 1.76 (s, 3H, 3-CH₃), 2.20 (dd, 1H), 2.27 (s, 3H, acetate-CH₃), 2.49 (m, 3H), 3.86 (s, 3H, OCH₃), 4.40 and 4.71 (2s, 2 x 1H, methylenedene-CH₂), 5.86 (s, 1H, 3-H), 6.64 (s, 1H, 6'-H),
25 7.21 ppm (s, 1H, 3'-H). [Compound 32 is hereinafter also referred to as COMPOUND "O" or 120276]

**Example 12**

1-Methylidene-6-(2'-hydroxyphenyl)methyl-5,5-dimethylcyclohex-2-ene (34):

This compound was prepared from 5,5-dimethylcyclohex-2-en-1-one (11) and 2-(tert-butyl)dimethylsilyloxybenzyl

bromide (9) in three steps in the manner previously described for the synthesis of olefin 16, affording the desired phenol as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.90 and 1.15 (2s, 2 x 3H, geminal-CH₃'s), 1.85 and 2.24 (d of ABq, 2H, J_{AB} = 18.8 Hz, J_A = 5.5 Hz, J_B = 0 Hz, 4-H), 2.06 (dd, 1H, J = 11.4, 3.2 Hz, 6-H), 2.30 and 2.88 (d of ABq, 2H, J_{AB} = 13.5 Hz, J_A = 11.4 Hz, J_B = 3.4 Hz, benzylic-CH₂), 4.20 and 4.69 (2s, 2 x 1H, methylenidene-CH₂), 4.61 (s, 1H, OH), 5.77 (ddd, 1H, J = 7.8, 5.4, 5.4 Hz, 3-H), 6.09 (dd, 1H, J = 7.5, 2.2 Hz, 2-H), 6.75 (dd, 1H, J = 7.1, 0.8 Hz, 3'-H), 6.82 (ddd, 1H, J = 8.4, 7.3, 1.1 Hz, 5'-H), 6.97 (dd, 1H, J = 5.9, 1.5 Hz, 6'-H), 7.05 ppm (ddd, 1H, J = 9.3, 7.8, 1.7 Hz, 4'-H). [Compound 34 is hereinafter also referred to as COMPOUND "C" or 120363]

15 Example 13

1-Methylenidene-2-(2'-hydroxyphenyl)methyl-5,5-dimethylcyclohexane (35):

This compound was prepared from 5,5-dimethylcyclohex-2-en-1-one (11) and 2-(tert-butyl)dimethylsilyloxybenzyl bromide (9) in four steps in the manner previously described for the synthesis of olefin 16, affording the desired olefin as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.97 and 1.01 (2s, 2 x 3H, geminal-CH₃'s), 2.09 (ddd, 1H) and 2.27 (ddd, 1H) [6-H], 2.18 (dd, 1H, 2-H), 2.70 and 2.84 (d of ABq, 2H, benzylic-CH₂), 4.37 (sl d, 1H) and 4.63 (s, 1H) [methylenidene-CH₂], 4.72 (s, 1H, OH), 6.72 (d, 1H, 3'-H), 6.81 (dd, 1H, 5'-H), 7.03 (d, 1H, 6'-H), 7.04 ppm (dd, 1H, 4'-H). [Compound 35 is hereinafter referred to as COMPOUND "D" or 120370]


30 Example 14

trans-1-Methyl-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methylcyclohexan-1-ol (36):

To a solution of 2-[(2'-tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl] methylcyclohexan-1-one (27) (10 mg, 0.023 mmol) in 1 mL of anhydrous ether at -78°C was

added methylmagnesium bromide (8.0 μ L of a 3.0 M solution in ether, 0.024 mmol, 1.06 equiv). The reaction mixture was stirred at -78°C for 30 minutes and quenched with saturated aqueous NH_4Cl , extracted with ether, and the organic phase was dried over Na_2SO_4 and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 4:1) gave 10 mg (97%) of the desired tertiary alcohol as a colorless oil. To a solution of 10 mg (0.021 mmol) of this tertiary alcohol in 1 mL of dry THF at 0 °C was added tetra-(n-butyl)ammonium fluoride (25 μ L of a 1.0 M solution in THF, 0.025 mmol, 1.2 equiv), and the reaction mixture was allowed to stir for 20 minutes, then diluted with water, and extracted with ethyl acetate. The organic phase was washed with brine, dried over Na_2SO_4 and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 4:1) gave 6 mg (80%) of the desired tertiary alcohol as a colorless, viscous oil. ^1H NMR (400 MHz, CDCl_3) δ 1.32 (s, 3H, CH_3), 2.45 and 2.93 (d of ABq, 2H, benzylic- CH_2), 3.83 (s, 3H, OCH_3), 6.61 (s, 1H, 6'-H), 7.04 ppm (s, 1H, 3'-H). [Compound 36 is hereinafter also referred to as COMPOUND "Q" or 120136]

39

Example 151-Methylidene-6-(3'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene (38):

This compound was prepared from 5,5-dimethylcyclohex-2-en-1-one (11) (0.150 g, 1.21 mmol) and *m*-nitrobenzyl bromide (0.510 g, 2.42 mmol, 2.00 equiv) in three steps in the manner previously described for the synthesis of olefin 16, affording 42.7 mg (26% overall), of the nitro-diene as a pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 0.91 and 1.13 (2s, 2 x 3H, geminal- CH_3 's), 1.99 and 2.12 (d of ABq, 2H, benzylic- CH_2), 4.07 and 4.89 (2s, 2 x 1H, methylidene- CH_2), 5.77 and 6.00 (2dd, 2 x 1H, 2,3-H), 7.42 (dd, 1H, Ar-H), 7.59 (d, 1H, Ar-H), 7.96 (d, 1H, Ar-H), 8.00 ppm (s, 1H, Ar-H). [Compound 38 is hereinafter also referred to as COMPOUND "A" or 120117]

Example 166-(4'-Nitrophenyl)methyl-5,5-dimethylcyclohex-2-en-1-one (39):

This compound was prepared from 5,5-dimethylcyclohex-2-en-1-one (11) (0.600 g, 4.83 mmol) and *p*-nitrobenzyl bromide (1.581 g, 7.32 mmol) in the manner previously described for the synthesis of enone 13, affording 627 mg (50%), of the nitro-enone as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 1.02 and 1.18 (2s, 2 x 3H, geminal-CH₃'s), 2.83 and 3.10 (d of ABq, 2H, benzylic-CH₂), 6.00 (ddd, 1H, 2-H), 6.81 (ddd, 1H, 3-H), 7.38 and 8.10 ppm (ABq, 2 x 2H, Ar-H).

2-(4'-Nitrophenyl)methyl-3,3-dimethylcyclohexan-1-one (40):

An atmosphere of hydrogen was introduced to and maintained by a balloon to an evacuated 50 mL round-bottomed flask containing 6-(4'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-en-1-one (39) (14.0 mg, mmol) and tris(triphenylphosphine)rhodium chloride (Wilkinson's catalyst) (8.0 mg) in 6.5 mL anhydrous benzene. The yellow-orange solution was stirred at room temperature for 24 h, and then passed through a short silica gel column (hexanes/ethyl acetate, 3:1) to afford the 6.8 mg (48%) of the desired ketone as a pale yellow oil (R_f 0.43, 2:1 hexanes/ethyl acetate). ¹H NMR (400 MHz, CDCl₃) δ 0.86 and 1.23 (2s, 2 x 3H, geminal-CH₃'s), 2.50 (d, 1H, *J* = 13.0 Hz, 2-H), 2.66 and 3.17 (d of ABq, 2H, *J*_{AB} = 13.0 Hz, *J*_A = 1.6 Hz, *J*_B = 9.6 Hz, benzylic-CH₂), 7.37 (d, 2H, *J* = 9.6 Hz, 2',6'-H), 8.09 ppm, (d, 2H, *J* = 9.6 Hz, 3',5'-H). [Compound 40 is hereinafter also referred to as COMPOUND "V" or 120211]

Example 171-Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene (41):

This compound was prepared from 6-(4'-nitrophenyl)
5 methyl-5,5-dimethylcyclohex-2-en-1-one (39) (133 mg, 0.514
mmol) in the manner previously described for the synthesis
of olefin 16, with the following procedural changes.
Three equivalents of (trimethyl)silylmethylolithium were
used, and the subsequent elimination step required 48 h to
10 go to completion, affording 120 mg (86%) of the nitro-
diene as a colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 0.92
and 1.12 (2s, 2 x 3H, geminal-CH₃'s), 2.58 (s, 3H, Ar-CH₃),
4.05 and 4.64 (2s, 2 x 1H, methylidene-CH₂), 5.70 (ddd, 1H,
3-H), 6.03 (dd, 1H, 2-H), 6.98 (s, 1H, Ar-H), 6.99 and
15 7.88 ppm (2d, 2 x 1H, Ar-H). [Compound 41 is hereinafter
also referred to as COMPOUND "T" or 120120]

Example 186-(4'-Nitrophenyl)methyl-3,5,5-trimethylcyclohex-2-en-1-one (42):

20 This compound was prepared from isophorone (2.065 g,
14.94 mmol) and p-nitrobenzyl bromide (4.06 g, 18.80 mmol,
1.25 equiv) in the manner previously described for the
synthesis of enone 13, affording 1.891 g (46%), of the
nitro-enone as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃)
25 δ 0.98 and 1.13 (2s, 2 x 3H, geminal-CH₃'s), 1.92 (s, 3H,
3-CH₃), 2.17 and 2.31 (ABq, 2H, J_{AB} = 18.5 Hz, 4-H), 2.38
(dd, 1H, J = 9.0, 3.3 Hz, 6-H), 2.75 and 3.05 (d of ABq,
2H, J_{AB} = 14.0 Hz, J_A = 3.2 Hz, J_B = 8.9 Hz, benzylic-CH₂),
5.84 (s, 1H, 2-H), 7.33 (d, 2H, J = 8.2 Hz, Ar-H) and 7.53
30 ppm (d, 2H, J = 8.2 Hz, Ar-H).

1-Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-3,5,5-trimethylcyclohex-2-ene (43):

This compound was prepared from 6-(4'-nitrophenyl)
methyl-3,5,5-trimethylcyclohex-2-en-1-one (42) (21.0 mg,
35 0.077 mmol) in the manner previously described for the

synthesis of olefin 16, using three equivalents of (trimethyl)silylmethylolithium, and allowing 18 h for the subsequent elimination step, affording 3.5 mg (16%) of the nitro-diene as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃)
5 δ 0.89 and 1.15 (2s, 2 x 3H, geminal-CH₃'s), 1.96 and 2.10 (ABq, 2H, benzylic-CH₂), 2.58 (s, 3H, Ar-CH₃), 2.92 (dd, 1 H, 6-H), 3.96 and 4.54 (2s, 2 x 1H, methyldiene-CH₂), 5.82 (s, 1H, 2-H), 6.98 (s, 1H, Ar-H), 6.99 and 7.88 ppm (2d, 2 x 1H, Ar-H). [Compound 43 is hereinafter also referred
10 to as COMPOUND "U" or 120168]

Examples 19-20


2-(4'-Nitrophenyl)methylcyclohexan-1-one (44):

To a solution of diisopropylamine (342 μL, 2.45 mmol, 1.2 equiv) in 5 mL of anhydrous THF at 0°C was added *n*-
15 butyllithium (1.63 mL of a 1.6 M solution in hexane), and the mixture was stirred at this temperature for 15 minutes before cooling to -78°C. Cyclohexanone (221 μL, 2.04 mmol, 1.0 equiv) in 2 mL of anhydrous THF was then added dropwise, stirred at -78°C for 1 h followed by *p*-
20 nitrobenzyl bromide (880 mg, 4.08 mmol, 2.00 equiv) in 2 mL of THF, added dropwise to the resulting enolate. The reaction mixture was stirred at room temperature for 17 h, and then quenched with aqueous saturated NH₄Cl, and extracted with ether. The organic phase was dried over
25 Na₂SO₄ and concentrated under diminished pressure to a solid residue that was purified by flash chromatography (silica gel, hexanes / ethyl acetate, 85:15), which afforded 300 mg (64%) of the desired ketone as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 1.41 (m, 1H), 1.66 (m,
30 2H), 1.88 (m, 1H), 2.08 (m, 2H), 2.33 (m, 1H), 2.45 (m, 1H), 2.57 (m, 1H, 2-H), 2.59 and 3.29 (d of ABq, 2H, benzylic-CH₂), 7.34 (d, 2H, Ar-H), 8.12 ppm (d, 2H, Ar-H). [Compound 44 is hereinafter also referred to as COMPOUND "G" or 120138]

trans-2-(4'-Nitrophenyl)methylcyclohexan-1-ol (45):

To a stirring solution of 2-(4'-nitrobenzene) methylcyclohexan-1-one (44) in 5 mL of methanol at 0°C was added portionwise sodium borohydride, and the reaction mixture was allowed to stir at 0°C for 1.5 h before quenching with saturated aqueous NH₄Cl. The methanol was removed under diminished pressure, and the resultant aqueous residue was extracted with ethyl acetate. The organic phase was washed with brine, dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 4:1) gave 10 mg (20%) of the desired alcohol 45, along with 18 mg (36%) of the diastereoisomeric alcohol 46 as colorless oils. Data for alcohol 45: ¹H NMR (400 MHz, CDCl₃) δ 0.92 (m, 1H), 1.11 (m, 1H), 1.28 (m, 3H), 1.60 (m, 2H), 1.76 (m, 1H), 2.02 (m, 1H, 2-H), 2.51 and 3.59 (d of ABq, 2H, benzylic-CH₂), 3.27 (m, 1H, 1-H), 7.34 (d, 2H, Ar-H), 8.15 ppm (d, 2H, Ar-H). [Compound 45 is hereinafter also referred to as COMPOUND "I" or 120154.]

44

**Example 21**

(2R)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethyl-cyclohexane (49):

To a flame-dried 10 mL round-bottomed flask containing
 5 (1*S*,3*R*)-4-methylidene-1-bromo-3-[2' (tert-butyl)dimethyl-silyloxy-4'-bromo-5'-methoxyphenyl]methyl-2,2-dimethyl-

cyclohexane (47) (19.5 mg, 0.036 mmol) in 1 mL anhydrous benzene with 2 mg AIBN at room temperature was added *n*-Bu₃SnH (39 μ L, 0.144 mmol, 4.0 equiv). After 90 min, TLC analysis indicated virtually complete consumption of starting material, and formation of a slightly less polar product. Carbon tetrachloride (200 μ L) was added, and after 1 h at room temperature followed by 1.5 h at 0°C, 2 mL THF and 200 μ L 1.0 M tetra-(*n*-butyl)ammonium fluoride solution in THF were added. After 10 min at 0°C, pH 7 buffer was added, and the reaction mixture was extracted with hexanes. The resultant organic solution was dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, 10% ethyl acetate in hexanes) afforded 7.5 mg (61%) of the debromophenol as a colorless oil. The 400 MHz ¹H NMR spectrum and TLC elution properties of this compound were identical to those reported for the racemic compound. [Compound 49 is hereinafter also referred to as COMPOUND "N" or 120037]

20 Example 22

(2*S*)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethyl-cyclohexane (52):

This compound was prepared from (1*S*,3*S*)-4-methylidene-1-bromo-3-[2'-(*tert*-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-2,2-dimethylcyclohexane (50) (25.0 mg, 0.047 mmol) in the manner described for the synthesis of derivative 49, affording 5.5 mg (35%) of the debromophenol as a colorless oil, along with the remainder of the mass balance as deprotected starting material. The 400 MHz ¹H NMR spectrum and TLC elution properties of this compound were identical to those reported for the racemic compound. [Compound 52 is hereinafter also referred to as COMPOUND "X" or 120158]

Example 23

(1S,3S,5S)-4-Methylidene-1-bromo-5-hydroxy-3-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-2,2-dimethylcyclohexane (54):


- 5 To a flame-dried 25 mL round-bottomed flask containing (1S,3S)-4-methylidene-1-bromo-3-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-2,2-dimethylcyclohexane (53) (22.8 mg, 0.050 mmol) in 2.5 mL anhydrous dichloromethane at room temperature was added selenium dioxide (5.5 mg, 0.050
10 mmol, 1.00 equiv) and anhydrous t-butyl hydroperoxide (60 μ L of a 3.0 M solution in 2,2,4-trimethylpentane, 1.00 mmol, 2.00 equiv), and the mixture was allowed to stir at room temperature for 48 h, at which time the solvent was removed by rotary evaporation. Purification by flash
15 column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 20 mg (84%) of the hydroxy-cyclocymopol acetate as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 0.94 and 1.24 (2s, 2 x 3H, geminal- CH_3 's), 2.23 and 2.41 (dd of ABq, 2H, $J_{\text{AB}} = 14.0$ Hz, $J_{\text{A}} = 11.7$, 3.5 Hz, $J_{\text{B}} = 4.2$, 4.2 Hz, 6-H), 2.32 (s, 3H, acetate- CH_3), 2.73 and 2.86 (dd of ABq, 2H, $J_{\text{AB}} = 15.2$ Hz, $J_{\text{A}} = 11.3$, 0.5 Hz, $J_{\text{B}} = 15.3$, 3.0 Hz, benzylic- CH_2), 3.84 (s, 3H, OCH_3), 4.31 (br s, 1H, 1-H), 4.55 (dd, 1H, $J = 11.7$, 4.4 Hz, 5-H), 4.69 and 5.03 (2s, 2 x 1H, methylidene- CH_2), 6.75 (s, 1H, 6'-H),
20 7.19 ppm (s, 1H, 3'-H).

(4S,6S)-1-Methylidene-4-bromo-5-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene (55):

- To a flame-dried 10 mL round-bottomed flask containing (1S,3S,5S)-4-methylidene-1-bromo-5-hydroxy-3-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-2,2-dimethylcyclohexane
30 (54) (6.8 mg, 0.014 mmol) in 2 mL anhydrous benzene at room temperature was added Burgess reagent [(methoxycarbonylsulfamoyl)triethylammonium hydroxide, inner salt] (8.5 mg, 0.036 mmol, 2.5 equiv), and the mixture was
35 allowed to stir for 12 h. Removal of the solvent under diminished pressure, followed by purification by flash

47

column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 4.8 mg (74%) of the desired diene as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 0.94 and 1.18 (2s, 2 x 3H, geminal- CH_3 's), 2.33 (s, 3H, acetate- CH_3), 3.78 (s, 3H, OCH_3), 4.69 and 4.78 (2s, 2 x 1H, methyldiene- CH_2), 5.44 and 5.50 (2dd, 2 x 1H, 5.6-H), 6.64 (s, 1H, 6'-H), 7.00 ppm (s, 1H, 3'-H). [Compound 55 is hereinafter also referred to as COMPOUND "E" or 120261]



Example 24

(1R,3R)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane (56) and
(1S,3R)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane (57):

This set of diastereomeric alcohols was prepared from (2R)-1-methylidene-2-[2'-(tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenylmethyl-3,3-dimethylcyclohexane (48) (0.750 g, 1.66 mmol) in the manner previously described for the synthesis of alcohol 54, affording 741 mg (95%) of an inseparable 1:1 mixture of diastereomeric allylic alcohols. A portion (40 mg, 0.085 mmol) of this diastereomeric mixture was subjected to deprotection of the silylphenol in the usual manner, yielding mixture of free phenols, separable by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution), to give 14.0 mg (46%) of the less polar 1R,3R diastereomer (56), along with 13.0 mg (43%) of the more polar 1S,3R diastereomer (57) as white solids. Data for 56: ¹H NMR (400 MHz, CDCl₃) δ 0.93 and 1.12 (2s, 2 x 3H, geminal-CH₃'s), 1.70 (m, 2H, 1-H), 1.94 (m, 3H, 6,3-H), 2.65 and 3.00 (d of ABq, 2H, J_{AB} = 14.0 Hz, J_A = 3.1 Hz, J_B = 14.0 Hz, benzylic-CH₂) 3.84 (s, 3H, OCH₃), 4.37 (br s, 1H, 5-H), 4.39 and 4.92 (2s, 2 x 1H, methylidene-CH₂), 6.58 (s, 1H, 6'-H), 7.02 ppm (s, 1H, 3'-H). Data for 57: ¹H NMR (400 MHz, CDCl₃) δ 1.00 and 1.02 (2s, 2 x 3H, geminal-CH₃'s), 2.45 (dd, 1H, J = 11.5, 3.2 Hz, 3-H), 2.70 and 2.88 (d of ABq, 2H, J_{AB} = 14.1 Hz, J_A = 13.1 Hz, J_B = 4.2 Hz, benzylic-CH₂) 3.80 (s, 3H, OCH₃), 4.40 (br dd, 1H, J = 11.5, 4.5 Hz, 5-H), 4.47 and 4.86 (2s, 2 x 1 H, methylidene -CH₂), 6.61 (s, 1H, 6'-H), 7.94 ppm (s, 1H, 3'-H). [Compound 56 is hereinafter also referred to as COMPOUND "R" or 120243]

Example 25

(1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane (59) and (1R,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane (60):

This set of diastereomeric alcohols was prepared from (2S)-1-methylidene-2-[2'-(tert-butyl)dimethylsilyloxy-4'-bromo-5'-methoxyphenyl]methyl-3,3-dimethylcyclohexane (51) (0.340 g, 0.75 mmol) in the manner previously described for the synthesis of alcohol 54, affording 302 mg (86%) of an inseparable 1:1 mixture of diastereomeric allylic alcohols (58). A portion (21.6 mg, 0.046 mmol) of this diastereomeric mixture was subjected to deprotection of the silylphenol in the usual manner, yielding mixture of free phenols, separable by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution), to give 7.2 mg (44%) of the less polar 1S,3S diastereomer (59), along with 6.5 mg (40%) of the more polar 1R,3S diastereomer (60) as white solids. The 400 MHz ¹H NMR spectrum and TLC elution properties of each diastereomer 59 and 60 were identical to those previously reported for their respective enantiomeric hydroxy compounds 56 and 57. [Compound 59 is hereinafter also referred to as COMPOUND "B" or 120263]

Example 26

(3S)-2-Methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexan-1-one (61):

To a flame-dried 50 mL round-bottomed flask containing a 1:1 mixture of silyl-protected phenols 58 (165.0 mg, 0.352 mmol) in 12 mL dichloromethane with 2% pyridine at room temperature was added Dess-Martin periodinane reagent (165 mg, 0.386 mmol, 1.1 equiv), and the mixture was stirred for 30 min. The reaction mixture was then transferred to a 125 mL erlynmeyer flask containing 50 mL 1:1 saturated aqueous NaHCO₃/10% Na₂S₂O₃, and the mixture was stirred for an additional 90 min. The mixture was then




extracted with dichloromethane (2 x 40 mL), and the organic phase was washed with brine, dried over Na₂SO₄, and concentrated under diminished pressure. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, 9:1) afforded 150 mg (91 %) of the desired enone as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 0.23 (s, 6H, Si(CH₃)₂), 1.00 [s, 9H, SiC(CH₃)₃], 1.12 and 1.15 (2s, 2 x 3H, geminal-CH₃'s), 1.62 (dddd, 1 H, J = 9.9, 6.6, 5.4, 1.3 Hz, 1-H_{eq}), 2.01 (dddd, 1H, J = 14.0, 13.8, 8.9, 2.3 Hz, 1-H_{ax}), 2.24 and 2.50 (d of ABq, 2H, J_{AB} = 11.9 Hz, J_A = 11.9 Hz, J_B 2.8 Hz, benzylic-CH₂), 2.46 and 2.48 (ABq, 2H, J_{AB} = 5.4 Hz, 6-H), 3.07 (dd, 1H, J = 13.3, 3.6 Hz, 3-H), 3.80 (s, 3H, OCH₃), 4.46 (d, 1H, J = 1.6 Hz) and 5.54 (d, 1H, J = 1.8 Hz) [methylidene-CH₂], 6.41 (s, 1H, 6'-H), 6.93 ppm (s, 1H, 3'-H).

(1R,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-1,4,4-trimethylcyclohexane (62) and (1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-1,4,4-trimethylcyclohexane (63).


To a flame-dried 50 mL round-bottomed flask containing a solution of (3S)-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexan-1-one (61) (150.0 mg, 0.322 mmol) in 15 mL THF at -70°C under nitrogen atmosphere was added methyllithium (0.60 mL of a 1.40 M solution in ether, 0.840 mmol, 2.61 equiv), and the mixture was allowed to stir for 5 min before quenching with saturated aqueous NH₄Cl. Upon warming to room temperature, the reaction mixture was extracted with ethyl acetate, and the organic phase was washed with brine, dried over Na₂SO₄, and concentrated under diminished pressure gave a 3:1 (1R,3S: 1S,3S) mixture of the diastereomeric tertiary hydroxyls. Purification by flash column chromatography (silica gel, hexanes/ethyl acetate, gradient elution) afforded 28 mg (18%) of the less polar, minor 1S,3S isomer (63), along with 88 mg (57%) of the more polar, major 1R,3S isomer (62), as well as 30.2 mg

(20%) recovered starting material. The diastereomeric alcohols were then independently converted to the corresponding free phenols in the usual manner, providing the trans, 1*R*,3*S* isomer (62) ¹H NMR (400 MHz, CDCl₃) δ 0.84
5 and 1.04 (2s, 2 x 3H, geminal-CH₃'s), 1.39 (s, 3H, 5-CH₃), 2.43 (br dd, 1H, *J* = 11.3, 2.9 Hz, 3-H), 2.72 and 2.85 (d of ABq, 2H, *J*_{AB} = 16.1 Hz, *J*_A = 3.1 Hz, *J*_B = 11.5 Hz, benzylic-CH₂) 3.77 (s, 3H, OCH₃), 4.57 and 5.16 (2s, 2 x 1H, methyldene-CH₂), 6.63 (s, 1H, 6'-H), 6.93 ppm (s, 1H,
10 3'-H); and the cis, 1*S*,3*S* isomer (63) ¹H NMR (400 MHz, CDCl₃) δ 0.77 and 1.08 (2s, 2 x 3H, geminal-CH₃'s), 1.36 (s, 3H, 5-CH₃), 2.65 and 2.82 (d of ABq, 2H, *J*_{AB} = 16.0 Hz, *J*_A = 3.0 Hz, *J*_B = 11.8 Hz, benzylic-CH₂), 2.97 (br dd, 1H, *J* = 11.7, 2.5 Hz, 3-H), 3.79 (s, 3H, OCH₃), 4.64 and 4.96
15 (2s, 2 x 1H, methyldene-CH₂), 6.73 (s, 1H, 6'-H), 6.92 ppm (s, 1H, 3'-H). [Compound 63 is hereinafter also referred to as COMPOUND "J" or 120286, and Compound 62 is hereinafter also referred to as COMPOUND "P" or 120273]

52




Representative derivative compounds include:




COMPOUND A [120117]

1-Methylidene-6-(3'-
nitrophenyl)methyl-5,5-
5 dimethylcyclohex-2-ene




COMPOUND B [120263]

(1*S*,3*S*)-1-Hydroxy-2-
methylidene-3-(2'-hydroxy-
4'-bromo-5'-methoxyphenyl)
methyl-4,4-dimethylcyclo-
hexane




COMPOUND C [120363]

1-Methylidene-6-(2'-
hydroxyphenyl)methyl-5,5-
dimethylcyclohex-2-ene




COMPOUND D [120370]

1-Methylidene-2-(2'-
hydroxyphenyl)methyl-5,5-
dimethylcyclohexane



COMPOUND E [120261]


(4*S*,6*S*)-1-Methylidene-4-
bromo-5-(2'-acetoxy-4'-
bromo-5'-methoxyphenyl)
methyl-5,5-dimethylcyclo-
15 hex-2-ene




COMPOUND F [120032]

1-Methylidene-6-(2'-
acetoxy-4'-bromo-5'-
methoxyphenyl)methyl-5,5-
dimethyl cyclohex-2-ene


54




COMPOUND G [120138]
2-(4'-Nitrophenyl)methyl-
cyclohexan-1-one




COMPOUND H [120299]
8-(2'-Acetoxy-4'-bromo-5'-
methoxyphenyl)methyl-
5,7,7-trimethylspiro
[2,5]oct-4-ene




COMPOUND I [120154]
5 *trans*-2-(4'-Nitrophenyl)
methylcyclohexan-1-ol




COMPOUND J [120286]
(1*S*,3*S*)-1-Hydroxy-2-
methylidene-3-(2'-hydroxy-
4'-bromo-5'-methoxyphenyl)
methyl-1,4,4-trimethyl-
cyclohexane



COMPOUND K [120192]
1-Methylidene-2-(2'-
hydroxy-4'-bromo-5'-
methoxyphenyl)methyl-3,3-
10 dimethylcyclopentane




COMPOUND L [120260]
(5*R*,6*S*)-1-methylidene-6-
(2'-acetoxy-4'-bromo-5'-
methoxyphenyl)methyl-5-
methylcyclohex-2-ene




COMPOUND M [120019]

1-Methylidene-2-(2'-
hydroxy-4'-bromo-5'-
methoxyphenyl)methyl-3,3-
5 dimethylcyclohexane




COMPOUND N [120037]

(2R)-1-methylidene-2-(2'-
hydroxy-4'-bromo-5'-
methoxyphenyl)methyl-3,3-
dimethylcyclohexane




COMPOUND O [120276]

(5R,6S)-1-Methylidene-6-
(2'-acetoxy-4'-bromo-5'-
methoxyphenyl)methyl-3,5-
10 dimethylcyclohex-2-ene




COMPOUND P [120273]

(1R,3S)-1-Hydroxy-2-
methylidene-3-(2'-hydroxy-
4'-bromo-5'-methoxyphenyl)
methyl-1,4,4-trimethyl-
cyclohexane



COMPOUND Q [120136]


trans-1-Methyl-2-(2'-
hydroxy-4'-bromo-5'-
methoxyphenyl)methyl-
15 cyclohexan-1-ol



COMPOUND R [120243]


(1R,3R)-1-Hydroxy-2-
methylidene-3-(2'-hydroxy-
4'-bromo-5'-methoxyphenyl)
methyl-4,4-dimethylcyclo-
hexane

56




COMPOUND S [120275]

5 *cis*-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3,5-trimethylcyclohexane




COMPOUND T [120120]

1-Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene




COMPOUND U [120168]

10 1-Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-3,5,5-trimethylcyclohex-2-ene




COMPOUND V [120211]

2-(4'-Nitrophenyl)methyl-3,3-dimethylcyclohexan-1-one




COMPOUND W [120033]

15 1-Methylidene-6-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene



COMPOUND X [120058]

(2*S*)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane



COMPOUND Y [120125]

2-(2'-Hydroxy-4'-bromo-5'-methoxyphenyl)methylcyclohex-1-one

5 Androgen Receptor Activity

Utilizing the "cis-trans" or "co-transfection" assay described by Evans et al., Science, 240:889-95 (May 13, 1988), the disclosure of which is herein incorporated by reference, the derivative compounds of Examples 1-26 were
10 tested and found to have strong, specific antagonist activity for the intracellular receptor for androgen. This assay is described in further detail in U.S. Patent Nos. 4,981,784 and 5,071,773, the disclosures of which are incorporated herein by reference. The co-transfection
15 assay provides a method for identifying functional ligands (either agonists which mimic, or antagonists which inhibit, the effect of hormones), and quantifying their activity for ligand-responsive receptor proteins. In this regard, the co-transfection assay mimics an in vivo system
20 in the laboratory. Importantly, activity in the co-transfection assay correlates very well with known in vivo activity, such that the co-transfection assay functions as a quantitative predictor of a tested compounds in vivo pharmacology. See, e.g., T. Berger et al. 41 J. Steroid
25 Biochem. Molec. Biol., 773 (1992), the disclosure of which is herein incorporated by reference.

In the co-transfection assay, a cloned gene for an intracellular receptor (e.g., androgen receptor) is introduced by transfection (a procedure to induce cells to

take up foreign genes) into a background cell substantially devoid of endogenous intracellular receptors. This introduced gene directs the recipient cells to make the intracellular receptor protein. A second gene is also
5 introduced (co-transfected) into the same cells in conjunction with the intracellular receptor gene. This second gene functions as a reporter for the transcription-modulating activity of the target intracellular receptor. Thus, the reporter acts as a surrogate for the products
10 normally expressed by a gene under control of the target receptor and its natural hormone. A preferred reporter gene is one which expresses the firefly enzyme luciferase.

The co-transfection assay can detect small molecule agonists or antagonists of target intracellular receptors.
15 Exposing the cells to an agonist ligand increases reporter activity in the transfected cells. This activity can be conveniently measured, e.g., by increasing luciferase production, which reflects ligand-dependent, intracellular receptor-mediated increases in reporter transcription. To
20 detect antagonists, the co-transfection assay is carried out in the presence of a constant concentration of an agonist (e.g., for androgen receptor, dihydrotestosterone) known to induce a defined reporter signal. Increasing concentrations of a test antagonist will decrease the
25 reporter signal (e.g., luciferase production). The co-transfection assay is therefore useful to detect both agonists and antagonists of specific intracellular receptors. It determines not only whether a compound interacts with a particular intracellular receptor, but
30 whether this interaction mimics (agonizes) or blocks (antagonizes) the effects of the natural regulatory molecules on target gene expression, as well as the specificity and strength of this interaction.

Co-transfected cells are exposed to a medium to which
35 is added the potential ligand (compound) that is being evaluated. If the candidate compound diffuses into the cell, binds to the receptor, and the resulting receptor

complex functions as an agonist, it will subsequently bind to the co-transfected reporter gene and initiate transcription. Typically, the reporter gene is one that expresses luciferase, which is capable of catalyzing a light-emitting reaction with its substrate luciferin. Thus, after cell lysis and the introduction of luciferin, the amount of light produced relative to the concentration of candidate compound used in the assay provides a measure of the potency and efficacy of the compound tested. Antagonist activity is evaluated by adding the candidate ligand and a known agonist to the co-transfected cells. Suppression of agonist-induced luciferase production by the candidate compound, and hence the amount of light produced, indicates the candidate compound is an antagonist.

The androgen receptor activity of the derivative compounds of Examples 1-26 were demonstrated according to the following illustrative Examples.

Example 27

Plasmid pRShAR (produced by cloning the 3400 bp linear fragment of the human androgen receptor (hAR) from vector pGEM3Z (85 P.N.A.S. 7211 (1988)) into the Bam HI site of the pRS vector), which expresses the human androgen receptor was transfected into monkey kidney fibroblast (CV-1) cells along with reporter plasmid MTV-LUC via calcium phosphate precipitation as described in Berger et al. supra. After six hours, the cells were washed with phosphate-buffered saline (PBS) and incubated at 37°C with 95% O₂/5% CO₂ for 40 hours prior to harvest. After incubation, whole cell receptor extract was prepared by homogenizing the harvested cells in Tris-HCl buffer, pH=7.4, containing 30% glycerol, 1 mM EDTA, 12 mM monothioglycerol, 1 mM PMSF, and 0.5 M potassium chloride. The homogenate was incubated at 4°C for 60 min with resuspension every 10 min. The suspension was centrifuged (105,000 X g, 60 min) and the supernatant was collected

and flash frozen in liquid nitrogen and stored frozen at -70°C.

Aliquots of the whole cell extract containing transfected androgen receptor were incubated at 4°C for 24 hours with a constant concentration (5 nM) of tritiated dihydrotestosterone (DHT) and increasing concentrations (0 - 2.5×10^{-5} M) of the derivative Compounds A-Y. The concentration of bound tritiated progesterone was determined in each sample by the dextran-coated charcoal adsorption technique, as follows.

To a 500 μ l final volume incubation mixture, 400 μ l of 7.5% (w/v) dextran-coated charcoal suspension in gelatin phosphate buffer was added. The mixture was vortexed and incubated at 4°C for 10 min and then centrifuged at 3000 rpm for 10 min. The amount of bound tritiated hormone was determined by liquid scintillation spectrophotometry of an aliquot of the supernatant.

The androgen antagonist activity assay results are shown below in Table 1. Efficacy is reported as the % maximal response observed for each compound relative to 2-Hydroxy-flutamide, a compound known to exhibit androgen receptor antagonist activity. Also reported in Table 1 for each compound is its potency or IC_{50} (which is the concentration (nM), required to reduce the maximal response by 50%). Furthermore, the full androgen antagonist dose response profile of Compounds "A, B, C & D" are shown in FIGS. 2 and 3, relative to the antagonist dose response profile of 2-Hydroxy-flutamide, as shown in FIG. 1. In this regard, the androgen antagonist compounds of the present invention preferably show greater than 60% efficacy and are potent at less than 800 nM, more preferably show greater than 70% efficacy and are potent at less than 500 nM, and most preferably show efficacy of greater than 80% and are potent at less than 300 nM as antagonists to the androgen receptor. Further, the compounds of the present invention selectivity as androgen antagonist is preferably shown by a potency at least three times

greater, and more preferably at least five times greater than that found on other intracellular receptors (e.g., progesterone receptor, glucocorticoid receptor etc ...).

The specific activity of Compounds A-J was compared
5 relative to their antagonist activity on the human progesterone receptor (PR) utilizing CV-1 cells cotransfected with plasmid pRShPR-B, as altered at the Tau-1 location (e.g., PR-TI) [specifically, HPR-B was excised from the vector pGEM3Z (69 Cell 703 (1992))]; the Tau-1 fragment of
10 the glucocorticoid receptor was inserted into hPR-B at the unique HincII site in the N-terminal region; a Bst EII to BST bI fragment spanning the Tau-1 insertion was then used to replace the corresponding region in pRShPR-B]. A comparison of the AR and PR activity of Compounds A-J is
15 shown in Table 2. Efficacy on PR-TI is reported as the % maximal response observed for each compound, and is comparable to that found with RU-486, a compound known to exhibit progesterone receptor antagonist activity. Potency or IC₅₀ is as reported for AR-wt transfected CV-1
20 cells. As can be seen, the high specific activity androgen antagonist compounds of the present invention are, in almost all circumstances, at least several times less potent (e.g., require a much higher potency to achieve the same activity), and are often less efficacious as a
25 progesterone antagonist.

Table 1 Inhibitory IC₅₀, Efficacy (%) and Potency (nM) of Example Compounds A-Y as Androgen Antagonists.

		<u>Efficacy</u>	<u>Potency</u>
		(%)	(nM)
30	A	69	66
	B	85	180
	C	82	210
	D	92	220
	E	60	230
35	F	87	240
	G	79	250

62

	H	89	250
	I	85	290
	J	85	300
	K	91	330
5	L	88	370
	M	--	--
	N	90	378
	O	78	390
	P	88	420
10	Q	94	460
	R	70	500
	S	92	500
	T	88	545
	U	69	565
15	V	85	590
	W	89	610
	X	88	723
	Y	67	340

Table 2

	<u>Compound</u>	<u>CV-1 Cells</u>		<u>CV-1 Cells</u>	
		<u>AR-wt</u>		<u>PR-TI</u>	
		<u>Efficacy</u>	<u>Potency</u>	<u>Efficacy</u>	<u>Potency</u>
20		(%)	(nM)	(%)	(nM)
	A	69	66	45	3,800
	B	85	180	98	865
	C	82	210	20	>10,000
	D	92	220	73	3,500
25	E	60	230	20	>10,000
	F	87	240	53	820
	G	79	250	98	920
	H	89	250	26	160
	I	85	290	99	360
30	J	85	300	95	850

The derivative compounds were also individually tested for cross-reactivity with the other known intracellular receptor classes. This testing showed the compounds not

to have significant activity with the glucocorticoid receptor, mineralocorticoid receptor or estrogen receptor.

Pharmacological and Other Applications

As previously discussed, it has been recognized that
5 the co-transfection assay provides a functional assessment
of the ligand (compound) being tested as either an agonist
or antagonist of the specific genetic process sought to be
affected, and mimics an *in vivo* system in the laboratory.
Compounds which do not react with other intracellular
10 receptors, as determined by the co-transfection assay, can
be expected to result in fewer pharmacological side
effects. Because the co-transfection assay is conducted
in living cells, the evaluation of a compound provides an
early indicator of the potential toxicity of the candidate
15 compound at concentrations where a therapeutic benefit
would be expected.

As will be discernible to those skilled in the art,
the non-steroid androgen receptor antagonist compounds
disclosed can be readily utilized in pharmacological
20 applications where androgen receptor antagonist activity
is desired, and where it is desired to minimize cross
reactivities with other related intracellular receptors.
In *in vivo* applications of the invention include administra-
tion of the disclosed compounds to mammalian subjects, and
25 in particular to humans.

The compounds of the present invention are small
molecules which are relatively fat soluble or lipophilic
and enter the cell by passive diffusion across the plasma
membrane. Consequently, these compounds are well suited
30 for administration orally as well as by injection. Upon
administration, these compounds can selectively antagonize
androgen receptors and thereby modulate processes mediated
by these receptors.

The pharmaceutical compositions of this invention are
35 prepared in conventional dosage unit forms by incorporat-
ing an active compound of the invention, or a mixture of

- such compounds, with a nontoxic pharmaceutical carrier according to accepted procedures in a nontoxic amount sufficient to produce the desired pharmacodynamic activity in a mammalian and in particular a human subject.
- 5 Preferably, the composition contains the active ingredient in an active, but nontoxic, amount selected from about 5 mg to about 500 mg of active ingredient per dosage unit. This quantity depends on the specific biological activity desired and the condition of the patient.
- 10 The pharmaceutical carrier or vehicle employed may be, for example, a solid or liquid. A variety of pharmaceutical forms can be employed. Thus, when using a solid carrier, the preparation can be plain milled micronized in oil, tableted, placed in a hard gelatin or enteric-coated
- 15 capsule in micronized powder or pellet form, or in the form of a troche, lozenge, or suppository. When using a liquid carrier, the preparation can be in the form of a liquid, such as an ampule, or as an aqueous or nonaqueous liquid suspension. The following examples provide
- 20 illustrative pharmacological composition formulations:

Example 28

Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
25 1-methylidene-6-(3'-nitrophenyl)methyl-5,5- dimethylcyclohex-2-ene (Compound A)	140
Starch, dried	100
Magnesium stearate	<u>10</u>
30 Total	250 mg

The above ingredients are mixed and filled into hard gelatin capsules in 250 mg quantities.

Example 29

A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
5 Compound A	140
Cellulose, microcrystalline	200
Silicon dioxide, fumed	10
Stearic acid	10
Total	360 mg

- 10 The components are blended and compressed to form tablets each weighing 665 mg.

Example 30

Tablets, each containing 60 mg of active ingredient, are made as follows:

	Quantity (mg/tablet)
15 Compound A	60
Starch	45
Cellulose, microcrystalline	35
20 Polyvinylpyrrolidone (PVP) (as 10% solution in water)	4
Sodium carboxymethyl starch (SCMS)	4.5
Magnesium stearate	0.5
Talc	1.0
25 Total	150 mg

- 30 The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of PVP is mixed with the resultant powders, which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The SCMS, magnesium stearate, and talc, previously passed through a No. 60 mesh U.S. sieve, and then added to the granules

which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Example 31

Suppositories, each containing 225 mg of active
5 ingredient, may be made as follows:

Compound A	225 mg
Saturated fatty acid glycerides	<u>2,000 mg</u>
Total	2,225 mg

Consequently, for an understanding of the scope of the
10 present invention, reference is made to the following claims.

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat
15 necessary. The mixture is then poured into a suppository mold of normal 2g capacity and allowed to cool.

Example 32

An intravenous formulation may be prepared as follows:

Compound A	100 mg
20 Isotonic saline	1,000 mL
Glycerol	100 mL

The compound is dissolved in the glycerol and then the solution is slowly diluted with isotonic saline. The solution of the above ingredients is then administered
25 intravenously at a rate of 1 mL per minute to a patient.

The compounds of this invention also have utility when labeled as ligands for use in assays to determine the presence of androgen receptor. They are particularly useful due to their ability to selectively activate
30 androgen receptor, and can therefore be used to determine

the presence of such receptors in the presence of other related receptors.


Due to the selective specificity of the compounds of this invention for androgen receptor, these compounds can
5 be used to purify samples of androgen receptor *in vitro*. Such purification can be carried out by mixing samples containing androgen receptor with one or more of the derivative compounds disclosed so that the compound (ligand) binds to the receptor, and then separating out
10 the bound ligand/receptor combination by separation techniques which are known to those of skill in the art. These techniques include column separation, filtration, centrifugation, tagging and physical separation, and antibody complexing, among others.

15 While in accordance with the patent statutes, description of the preferred weight fractions, and processing conditions have been provided, the scope of the invention is not to be limited thereto or thereby. Various modifications and alterations of the present invention will be
20 apparent to those skilled in the art without departing from the scope and spirit of the present invention.


.68

We claim:

1. A compound exhibiting activity as an androgen receptor antagonist having the formulae:



or



5 wherein:

the dotted lines in the structure depict optional double bonds;

X is carbon, oxygen, or nitrogen;

10 R_1 is R_{17} , $-OR_{17}$, $-N(R_{17})(R_{17}')$, $-SR_{17}$, fluorine, chlorine, bromine, or $-NO_2$;

R_{17} and (R_{17}') , each independently, are hydrogen, saturated or unsaturated C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_5 - C_7 aryl, or C_7 aralkyl, said alkyl groups being branched or straight-chain;

R_2 is $-\text{NO}_2$, $-\text{N}(\text{OH})\text{R}_{17}$, fluorine, chlorine, bromine, iodine, R_{17} , $-\text{N}(\text{R}_{17})(\text{R}_{17})$, $-\text{SR}_{17}$, $-\text{S}(\text{O})-\text{R}_{17}$, $-\text{S}(\text{O})_2-\text{R}_{17}$, $-\text{CH}_2\text{OH}$, $-\text{C}(\text{O})-\text{H}$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{C}(\text{O})-\text{OCH}_3$, $-\text{C}=\text{CH}_2$, $-\text{C}-\text{CH}-\text{C}(\text{O})-\text{OCH}_3$, or R_{18} ;

5 R_{18} and (R_{18}) , each independently, are hydrogen, saturated or unsaturated C_1-C_6 alkyl, C_3-C_7 cycloalkyl, C_5-C_7 aryl, or C_7 aralkyl, said alkyl groups being branched or straight-chain which optionally may contain hydroxyl, aldehyde, ketone, nitrile, or ester groups;

10 R_3 is R_{17} or $-\text{OR}_{17}$;

R_4 is hydrogen, $-\text{OR}_{17}$, $-\text{OC}(\text{O})\text{R}_{17}$, $-\text{OC}(\text{O})\text{OR}_{17}$, $-\text{OC}(\text{O})\text{N}(\text{R}_{17})(\text{R}_{17})$, $-\text{OS}(\text{O})_2\text{R}_{17}$, or $-\text{OS}(\text{O})-\text{R}_{17}$;

R_5 is hydrogen or OR_{17} ;

R_6 is R_{17} ;

15 R_7 and R_8 , each independently, are R_{18} , or R_7 and R_8 together are a carbocyclic 3-8 member ring;

R_9 and R_{10} , each independently, are chlorine, bromine, or R_{17} , or R_9 and R_{10} combined are $=\text{O}$, except when $\text{X}=\text{O}$, R_9 and R_{10} are not present, and when X is N , then R_{10} is not present, or R_9 and R_{10} together are joined in a carbocyclic 3-8 member ring;

R_{11} and R_{12} , each independently, are $-\text{OR}_{17}$, R_{18} , are $=\text{O}$, or are $=\text{CH}_2$, except when R_{11} is attached to an sp^2 carbon atom in the ring, then R_{12} is not present and R_{11} is R_{18} ,

25 or R_{11} and R_{13} together are joined in a carbocyclic 3-8 member ring or are $-\text{O}-$ to form an epoxide;

R_{13} and R_{14} , each independently, are $-\text{OR}_{17}$ or R_{18} , except when R_{13} is attached to an sp^2 carbon atom in the ring, then R_{14} is not present and R_{13} is $-\text{OR}_{17}$ or R_{18} ;

30 R_{15} and R_{16} , each independently, are R_{18} or OR_{17} , or R_{15} and R_{16} together are $-\text{CH}_2-\text{O}-$ forming an epoxide, or R_{15} and R_{16} combined are $=\text{O}$ or $=\text{C}(\text{R}_{18})(\text{R}_{18})$, except when R_{15} is hydroxyl, then R_{16} is not hydroxyl, and when R_{15} is attached to an sp^2 carbon atom in the ring, then R_{16} is not present, and when R_{15} and R_{16} combined are $=\text{O}$, then R_1 , R_2 , R_3 , and R_4 cannot all be hydrogen nor can R_3 be OCH_3 when R_1 , R_2 , and

R₄ are all hydrogen, or R₁₅ and R₁₆ together are joined in a carbocyclic 3-8 member ring.

2. A compound according to claim 1, wherein said compound is an optically pure 2R diastereomer.

5 3. A compound according to claim 1, wherein said compound is a optically pure 2S diastereomer.

4. A compound according to claim 1, selected from the group consisting of 1-Methylidene-6-(3'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene, (1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane, 1-Methylidene-6-(2'-hydroxyphenyl)methyl-5,5-dimethylcyclohex-2-ene, 1-Methylidene-2-(2'-hydroxyphenyl)methyl-5,5-dimethylcyclohexane, (4S,6S)-1-Methylidene-4-bromo-5-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene, 1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene, 2-(4'-Nitrophenyl)methylcyclohexan-1-one, 8-(2'-Acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,7,7-trimethylspiro[2.5]oct-4-ene, trans-2-(4'-Nitrophenyl)methylcyclohexan-1-ol, (1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-1,4,4-trimethylcyclohexane, 1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclopentane, (5R,6S)-1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5-methylcyclohex-2-ene, 1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane, (2R)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethylcyclohexane, (5R,6S)-1-Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-3,5-dimethylcyclohex-2-ene, (1R,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-1,4,4-trimethylcyclohexane, trans-1-Methyl-2-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methylcyclohexan-1-ol, (1R,3R)-1-Hydroxy-2-methylidene-3-(2'-

hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethyl-
cyclohexane, cis-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-
methoxyphenyl)methyl-3,3,5-trimethylcyclohexane, 1-
Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-5,5-
5 dimethylcyclohex-2-ene, 1-Methylidene-6-(3'-methyl-4'-
nitrophenyl)methyl-3,5,5-trimethylcyclohex-2-ene, 2-(4'-
Nitrophenyl)methyl-3,3-dimethyl cyclohexan-1-one, 1-
Methylidene-6-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)
methyl-5,5-dimethylcyclohex-2-ene, (2S)-1-Methylidene-2-
10 (2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-3,3-dimethyl-
cyclohexane, and 2-(2'-Hydroxy-4'-bromo-5'-methoxyphenyl)
methylcyclohex-1-one.

5. A ligand-receptor complex formed by binding of a
compound of claim 1 to an androgen receptor.

15 6. A ligand-receptor complex formed by binding a
compound of claim 4 to a androgen receptor.

7. A pharmacological composition comprising a
pharmaceutically acceptable vehicle and one or more of the
compounds of claim 1.

20 8. A pharmacological composition comprising a
pharmaceutically acceptable vehicle and one or more of the
compounds of claim 4.

9. A method of purifying a enantiomer of a compound
of claim 1, comprising converting said diastereomer to an
25 acetate and separating the diastereomeric acetate.

10. The method of claim 9 wherein the separation is
carried out using HPLC.

11. A method of antagonizing androgen activity
comprising the in vivo administration of one or more of
30 the compounds of claim 1.

12. A method for treating a mammalian subject requiring androgen receptor antagonist therapy comprising administering to such subject a pharmaceutically effective amount of a compound of claim 1.

5 13. A method for modulating a process mediated by androgen receptors comprising causing said process to be conducted in the presence of at least one compound as set forth in claim 1.

10 14. A method for modulating a process mediated by androgen receptors comprising administering to a mammalian subject an amount, effective to moderate said process mediated by said androgen receptors, of a compound of claim 1.

15 15. A method for determining the presence of one or more androgen receptors comprising combining at least one compound of claim 1 with a sample containing one or more unknown receptors and determining whether said compound binds to any receptor in said sample.

20 16. A method of purifying androgen receptors comprising combining at least one compound of claim 1 with a sample containing androgen receptors, allowing said compound to bind said androgen receptors, and separating out the bound combination of said compound and said androgen receptors.

25 17. 1-Methylidene-6-(3'-nitrophenyl)methyl-5,5-dimethylcyclohex-2-ene, (1S,3S)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)methyl-4,4-dimethylcyclohexane, 1-Methylidene-6-(2'-hydroxyphenyl)methyl-5,5-dimethylcyclohex-2-ene, 1-Methylidene-2-(2'-hydroxyphenyl)
30 methyl-5,5-dimethylcyclohexane, (4S,6S)-1-Methylidene-4-bromo-5-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene, 1-Methylidene-6-(2'-acetoxy-4'-

- bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene,
trans-2-(4'-Nitrophenyl)methylcyclohexan-1-ol, (1S,3S)-1-
Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxy-
phenyl)methyl-1,4,4-methylcyclohexane, (5R,6S)-1-
5 Methylidene-6-(2'-acetoxy-4'-bromo-5'-methoxyphenyl)
methyl-3,5-dimethylcyclohex-2-ene, (1R,3S)-1-Hydroxy-2-
methylidene-3-(2'-hydroxy-4'-bromo-5'-methoxyphenyl)
methyl-1,4,4-trimethylcyclohexane, trans-1-Methyl-2-(2'-
hydroxy-4'-bromo-5'-methoxyphenyl) methylcyclohexan-1-ol,
10 (1R,3R)-1-Hydroxy-2-methylidene-3-(2'-hydroxy-4'-bromo-5'-
methoxyphenyl)methyl-4,4-dimethylcyclohexane, 1-
Methylidene-6-(3'-methyl-4'-nitrophenyl)methyl-3,5,5-
trimethylcyclohex-2-ene, 2-(4'-Nitrophenyl)methyl-3,3-
dimethyl cyclohexan-1-one, 1-Methylidene-6-(2'-hydroxy-4'-
15 bromo-5'-methoxyphenyl)methyl-5,5-dimethylcyclohex-2-ene,
(2S)-1-Methylidene-2-(2'-hydroxy-4'-bromo-5'-methoxy-
phenyl)methyl-3,3-dimethylcyclohexane, and 2-(2'-Hydroxy-
4'-bromo-5'-methoxyphenyl)methylcyclohex-1-one.




FIG. 1




FIG. 2




FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 94/11852

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C43/23 C07C69/017 C07C49/517 C07C205/45 C07C205/06
 C07C205/18 C07C39/23 A61K31/085 A61K31/22 A61K31/12
 A61K31/04 A61K31/05

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF NATURAL PRODUCTS, vol. 52, no.5, September 1989 - October 1989 COLUMBUS, OHIO, US, pages 1092-1099, M.E. WALL, ET AL.: 'Plant mutagenic agents, 7. Structure and antimutagenic properties of cymobarbatol and 4-isocymobarbatol, new cymopols from green alga (Cymopolia barbata)' see compound 2 ---	1
X	AGRICULTURAL AND BIOLOGICAL CHEMISTRY, vol. 54, no.1, January 1990 TOKYO JP, pages 121-123, A. TANAKA, ET AL.: 'Synthesis of (+/-)-cyclocymopol' see compounds 1,2,4 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 February 1995

Date of mailing of the international search report

1 6. 02. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

English, R

INTERNATIONAL SEARCH REPORT

Intern. Appl. Application No.
PCT/US 94/11852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PHYTOCHEMISTRY, vol. 21, no.3, 1982 OXFORD, GB, pages 2139-2141, O.J. MCCONNELL, ET AL.: 'Diastereoisomers of cyclocymopol monomethyl ether from Cymopolia barbata' see compounds 1a,1b,2a,2b ---	1
X	JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1, no.16, 1976 LETCHWORTH GB, pages 1696-1701, H.-E. HÖGBERG, ET AL.: 'The cymopols, a group of prenylated bromohydroquinones from the green calcareous alga Cymopolia barbata' see compounds 3,4 ---	1
X	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 110, no.10, 11 May 1988 WASHINGTON, DC US, pages 3296-3298, S. AOKI, ET AL.: 'Palladium-catalysed arylation of siloxycyclopropanes with aryl triflates. Carbon chain elongation via catalytic carbon-carbon bond cleavage' see table II, products in 2nd and 3rd entries ---	1
X	JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no.1, January 1990 LETCHWORTH GB, pages 49-51, K. LAUMEN, ET AL.: 'Enzymic preparation of enantiomerically pure cyclohexanols: ester synthesis by irreversible acyl transfer' see compound 1,1a ---	1-3
X	JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no.22, 15 November 1991 LETCHWORTH GB, pages 1591-1593, S. PAL, ET AL.: 'A highly regioselective 6-endo-aryl radical cyclisation: stereocontrolled synthesis of trans.octahydroanthracenes' see compound 4 ---	1

-/--

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 94/11852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMISTRY LETTERS, no.8, 1991 TOKYO JP, pages 1413-1416, K. NARASAKA, ET AL.: 'Rearrangement of allylic and propargylic alcohols catalysed by the combined use of tetrabutylammonium perrhenate(VII) and p-toluenesulphonic acid' see compound 7 ---	1
X	TETRAHEDRON, vol. 48, no.11, 13 March 1992 OXFORD GB, pages 2059-2068, K. NARASAKA, ET AL.: 'Rearrangement of allylic and propargylic alcohols catalysed by the combined use of tetrabutylammonium perrhenate(VII) and p-toluenesulphonic acid' see compounds 7,7' ---	1
X	JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no.8, 15 April 1992 LETCHWORTH GB, pages 596-568, C. DESTABEL, ET AL.: 'A novel sequence of radical rearrangements involving the 5-exo cyclisation of a 3-(methylenecyclopropyl)- propyl radical' see compounds 6,16 ---	1
X	SYNTHESIS, no.11, November 1992 STUTTGART DE, pages 1073-1075, S. PAL, ET AL.: 'A facile synthetic route to 1,1-disubstituted 2,3-dihydro-1H-benz[f]indene-4,9-diones' see compound 1b ---	1
X	TETRAHEDRON, vol. 42, no.20, 1986 OXFORD GB, pages 5637-5640, S. ANTUS, ET AL.: 'Synthesis of grisan' see compounds 7,8 ---	1
X	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 115, no.10, 19 May 1993 WASHINGTON, DC US, pages 3909-3917, J.-L. REYMOND, ET AL.: 'Antibody-catalysed hydrolysis of enol ethers' see page 3916, right column, line 23 - line 36 ---	1

	-/--	

INTERNATIONAL SEARCH REPORT

Intern. Appl. Application No
PCT/US 94/11852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 65, no.9, November 1992 TOKYO JP, pages 2421-2426, H. NAGANO, ET AL.: 'Radical-based synthesis of terpenoids. Steroselectivity in the trapping of radicals from the cyclisation of 3-(1-ethoxy-2-haloethoxy)- cyclohexenes' see compounds 21,21' ---	1
X	EXPERIENTIA, vol. 34, no.9, 15 September 1978 BASEL CH, pages 1124-1125, J.P. YARDLEY, ET AL.: 'A potent benzylamine analgesic: (-)-cis-2-(alpha-dimethylamino-m-hydroxy- benzyl)cyclohexanol' see compound 6 ---	1,3
X	BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, no.4, 1969 PARIS FR, pages 1362-1367, M. MOREAU, ET AL.: 'Hydroxy-4a hexahydro-1,2,3,4a,9a xanthene. III. Étude de la tautomérie anneau-chaîne' see compounds 6-10,12a,12b,13,14a,14b ---	1
X	JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 42, no.6, 1969 CALCUTTA, IN, pages 415-423, K. DAS GUPTA 'Hydrofluorene derivatives. I. Synthesis of 1,6- and 1,7-dimethyl- and 7-hydroxy-1-methylfluorenes' see compound XV ---	1
X	US,A,5 134 155 (P.J. CONNOLLY, ET AL.) 28 July 1992 see column 17, table 1, compounds 86,88-95 ---	1
X	CHEMICAL ABSTRACTS, vol. 66, no. 21, 22 May 1967 Columbus, Ohio, US; abstract no. 94773s, A.I. CHIRKO, ET AL.: 'Autooxidation of benzyl cycloparaffins' page 8859; see abstract, in particular compounds III,IV and 'phenyl(2-hydroxycyclohexyl)- methane' & ZHURNAL ORGANISCHESKOI KHIMII, vol. 3, no.1, 1967 pages 28-33, ---	1
	---	-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 94/11852

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROCEEDINGS OF THE INDIAN ACADEMY OF SCIENCES, SECTION A, vol. 86A, no.3, 1977 BANGALORE, IN, pages 317-325, J. CHARRAVARTY, ET AL.: 'Condensed cyclic and bridged-ring systems. VII. Acid-catalysed cyclisation of methyl-substituted benzylcyclohexanols. Factors influencing the nature of cyclisation products' see compounds 6, 11, 16 ---	1
P,X	WO,A,93 21145 (LIGAND PHARMACEUTICALS) 28 October 1993 see page 8 - page 10; claims 1-9; examples 7-22 -----	1-4,17

INTERNATIONAL SEARCH REPORT

I International application No.

PCT/US 94/ 11852

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-17
because they relate to subject matter not required to be searched by this Authority, namely:

SEE ATTACHED SHEET
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

CLAIMS SEARCHED INCOMPLETELY : 1-17

CLAIMS 1-17 ENCOMPASS SUCH A LARGE NUMBER AND VARIETY OF COMPOUNDS THAT A COMPLETE SEARCH IS NOT POSSIBLE ON ECONOMIC GROUNDS (GUIDELINES FOR EXAMINATION IN THE EPO, PART B, CHAPTER III, 3.7). THUS THE SEARCH WAS DIRECTED TOWARDS (BUT NOT LIMITED TO) COMPOUNDS HAVING VARIABLES AS REPRESENTED IN THE EXAMPLES AND IN CLAIMS 4, 17. FURTHERMORE, SINCE AN ABILITY TO ANTAGONISE ANDROGEN RECEPTORS AS THIS CANNOT BE DETERMINED FROM PRIOR ART DOCUMENTS UNLESS IT HAS BEEN SPECIFICALLY MENTIONED, THE SEARCH FOR CLAIMS 1-4 WAS NOT NECESSARILY LIMITED TO COMPOUNDS WITH THIS ACTIVITY.

REMARK : ALTHOUGH CLAIMS 11-14 ARE DIRECTED TO A METHOD OF TREATMENT OF THE HUMAN/ANIMAL BODY THE SEARCH HAS BEEN CARRIED OUT AND BASED ON THE ALLEGED EFFECTS OF THE COMPOUND.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/11852

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5134155	28-07-92	AU-A- 2058992	11-02-93
		EP-A- 0529854	03-03-93
		JP-A- 5221998	31-08-93
		US-A- 5315012	24-05-94
		US-A- 5250561	05-10-93

WO-A-9321145	28-10-93	AU-B- 4117093	18-11-93
		AU-B- 5664194	08-11-94
		CA-A- 2133325	28-10-93
		EP-A- 0637296	08-02-95
		WO-A- 9424080	27-10-94
